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INTRODUCTION 
 
        Siddha system is one of the ancient system of medicine which maintains the 
physical, mental and moral health for more than 5000 years by rendering service to 
human. 
"ÁÚôÀÐ ¯¼ø§¿¡ö ÁÕó¦¾É Ä¡Ìõ 
         ÁÚôÀÐ ¯ª§¿¡ö ÁÕó¦¾É º¡Öõ 
 ÁÚôÀÐ ­É¢§¿¡ö Å¡Ã¡¾¢Õì¸ 
          ÁÚôÀÐ º¡¨Å ÁÕó¦¾ÉÄ¡§Á" 
 
                                                - ¾¢ÕãÄ÷ 
According to Siddhar Thirumoolar, the concept of siddha system is to treat the 
man as a whole and not merely the disease alone. His definition on medicine states that a 
medicine is the one that not only cures the physical and psychological ailments but also 
prevents the ailments. Finally he emphasis that the purpose of medicine is to increase the 
longevity. 
  Siddhars are super human who, masters the wind, waves, tides, gravity & other 
elements and forces of nature. According to Siddhars the human body is the combination 
of 3 humours, 5 boothas, 7thathus  and 96 thatwas. 
Siddha system mainly focuses on the three humours vatha, pitha and kapha which 
are the fundamental principles and essential factors in the composition and constitution of 
the human body.When the normal equilibrium of three humours  is disturbed disease is 
caused, so the treatment  in Siddha system is aimed at keeping the three humours in 
equilibrium.The factors which affect the equilibrium are environment, climatic 
conditions, diet, physical activites and stress. 
Kirumi Yoni Rogam is one among the 4448 diseases. This disease is mainly due 
to aggrevated pitha humour which is evident from the quote mentioned below, 
              
            "À¸÷À¢ò¾ Å¢ó¨¾ÂÄ¡Ð §Á¸õ Å¡Ã¡Ð"[7] 
                                                                        
- §¾¨ÃÂ÷                    
 2 
 
                As per saint yougi, Kirumi Yoni Rogam is one among the 20 types of Yoni 
Rogam which can be correlated with specific leucorrhea (Trichomoniasis, Moneliasis etc) 
in Modern science. 
                   
                Reproductive health is closely associated with culture of a country as it is well 
appreciated from the poetic version of Saint Yougi i.e., excessive lust will be the 
precipitating factor for Kirumi Yoni Rogam. 
 
The  etiology & the signs and symptoms of kirumi yoni rogam,[1] 
Due to excessive lust, 
o Inflammation of the vulva, 
o Infection of vagina leads to increased vaginal discharge, 
o Pruritis vulva, 
o Vaginal discharge with odour and pain & it can be correlated with specific 
leucorrhea in modern science. 
 
                    Kirumi Yoni Rogam is one, which affects the women commonly and 
frequently. Women in any reproductive age group and even young girls are commonly 
affected by Kirumi Yoni Rogam. The incidence of Kirumi Yoni Rogam is found in 
women irrespective of their socio-economic status. 
                      Vaginal infection is more common in women of childbearing age & in older 
women (post menopausal period).The factors like increasing age, illiteracy, low 
socioeconomic status, high parity, induced abortion & place of delivery are all 
contributing factors for occurrence of vaginal discharge. 
                  The most common easily curable Sexually transmitted disease a relatively 
neglected area of research. Among women ,Trichomoniasis increases the number of HIV-
receptive cells in the genital tract. Untreated Trichomoniasis leads to an increased risk of 
HIV infection & associated adverse pregnancy outcomes. So there is a need for increased 
screening & treatment for this easily curable sexually transmissible infection.[4]               
Moniliasis is caused by candida albicans, a gram positive yeast like fungus. The 
patient complains of curdy white vaginal discharge with intense vulvovaginal pruritis. 
The predisposing factors are diabetes, pregnancy, use of broad spectrum antibiotics, 
combined oral contraceptive pills, steroids, immunosuppression-HIV, thyroid and 
parathyroid disease.[4] 
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Siddha formulations not only treat this disease but also strengthen the Uterus, 
vagina and corrects the deranged pitham without any undesirable effects. We are 
receiving more number of Krumi Yoni Rogam cases in our hospital which is the driving 
force behind to select this disease for my dissertation study.  
As preparation of the trial drug Padigara parpam is cost effective efficacious & 
easily available, I have choosen padigara parpam as my drug of choice for the treatment 
 
 
The main ingredient of  PADIGARA PARPAM are, 
 PADIGARAM (POTASH ALUM) [2] 
  
  
 Vehicle- GHEE are said to possess antioxidant & anticancer 
property. 
So there is a need to evaluate the safety and therapeutic efficacy of this classical 
Siddha formulation  mentioned in Kannusamy parambarai 
vaithiyam for scientific validation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 4 
 
 
 
AIM: 
         The purpose of this study is to evaluate the safety and efficacy of siddha mineral 
 
 
OBJECTIVES:  
  Collection of various Siddha literatures of the study. 
 To correlate the Siddha aspects of Kirumi yoni rogam to specific 
leucorrhea of modern medicine with respect to etiology,pathology and 
clinical features.         
  Mineral identification and authentication of the trial drug. 
 rug 
preparation (ref:Kannusaami Parambarai Vaithiyam,C. Kannusaami 
pillai,2006, P.No.382 &383). 
 To evaluate the biochemical and physicochemical analysis of the  trial 
drug. 
 To evaluate the safety profile of the trial drug in animal models (Acute, 
subacute OECD guidelines) . 
 To study the efficacy of the trial drug through an open clinical trial. 
 To study the cofactors related to the disease (i.e., age ,socioeconomic 
status). 
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REVIEW OF LITERATURES 
A.SIDDHA ASPECT 
KIRUMI YONI ROGAM 
 
SYNONYMS: 
                Vellai noi, Vettai noi, Piramegam, Piramiyam, Ozhukku noi.[5] 
 
DEFINITION: 
          "Å¡È¡É ¨º§Â¡¸ Á¢Ì¾¢ Â¡Öõ  
              ÅøÌÄ¢§Ä §º¡Ã¢ÂÐ ¦¸ðÎ §Á¾¡ý  
          àÈ¡É ¸¢ÕÁ¢¸é Á¢¸×ñ¼¡¸¢ 
              ¦¾¡¼Õ§Á ¿¨ÁîºÖ¼ý Å¢ÕôÀí ¸¡Ïõ  
          ¿¡É¡É ¿¡üÈÓ¼ Û¾¢Ãó §¾¡ýÚõ 
              ¿Å¢Ä§Å ÓÊÂ¡Ð ¸¨ªÂ¢ý §Å¸õ  
         ¸¡Ã¡É ä¸¢ÓÉ¢ º¢¸¢îº¡ º¡Ãõ  
               
                                       - ä¸¢ ÓÉ¢ 
 Due to excessive lust 
o Inflammation of the vulva, 
o Infection of vagina leads to increased vaginal discharge, 
o Pruritis vulva, 
o Blood stained vaginal discharge with odour and pain in females is called 
Kirumi Yoni Rogam. 
 
I.AETIOLOGY: 
I.ACCORDING TO YOOGI MUNI 
 
               "­ÂõÀ§Å ±ª¢§Â¡¨Ã Â¢¸úîº¢ ¦º¡øÄø 
                        ²üÈÁ¡õ ¦ÀÃ¢§Â¡¨Ã ²Åø ¦¸¡ûªø 
                ÒÂõÀ§Å ¦À¡ýÈ¨É§Â §º¡Ãï ¦ºö¾ø 
                        ¦À¡Õû¾¨É§Â À¸¢÷ò¾ø ¦ÀÕ¨Á ¦º¡øÄø 
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                ¿ÂõÀ§Å ¿õÀ¢É¡÷ìÌ ¿£¼ï ¦ºö¾ø 
                        ¿¡ð¼Á¡ ±ó§¿ÃÓõ ¦Àñ §À¡¸¢ò¾ø 
                ÀÂõÀ§Å ÀÂóÐ Åó¾ §À¨Ãì ¸¡ð¼ø 
                        ÀÆ¢ò¾ §À¡÷ À¢ÃÁ¢Âò¾¢ü ÀÓò À¡¼¡§Á 
                À¡¼¡¸ ¦Àñ §À¡¸ Á¢¸ Å¢ÕõÀ¢ô 
                        ÀÂ¢ýÈ¢ðÎô ÀðÊÉ¢§Â Á¢¸Å¢Õò¾ø 
                ¾¡¼¡¸ò ¾ý À¡ò¾¢ø ÝÎ ¾¡í¸ø 
                        ºÃºÁ¡öì ¸¡Ãò¨¾ Á¢¸ô ¦À¡º¢ò¾ø 
                °¼¡¸ ¯ôÒ¨ÃôÒò ÐÅ÷ôÒ Á¢ïºø 
                        ¯ì¸¢ÃÁ¡õ ÀÄÀÄÅ¡õ Å¢§ººõ ¦ºö¾ø 
                ¸¡¼¡É ÁÉì¸¢§Äºõ ¸¡ÃÁ¡É 
                        ¨¸ò¾§Ä¡Î Á¢Õì¸Ä¢Ð¸¡Ïì ¸¡§É"[9] 
                                         - ä¸¢ÓÉ¢ ¨Åò¾¢Â º¢ó¾¡Á½¢  
 
1.±ª¢§Â¡¨Ã ­¸úîº¢ ¦ºö¾ø             - Riduculating the downtrodden   
2.¦ÀÃ¢§Â¡¨Ã §Å¨Ä ¦º¡øÄø   - Commanding elders  
3.¦À¡ýÉ¡Ä¡É ¦À¡Õð¸¨ª §º¡Ãõ ¦ºö¾ø - Filching gold 
4.ÁüÈÅ÷ ¦À¡Õ¨ª «À¸Ã¢ò¾ø   - Filfering other things  
5.¦ÀÕ¨Á §Àºø     - Self boasting 
6.¿õÀ¢ÉÅ÷ìÌ ¿£¼õ §ºö¾ø   - Bringing loss to others 
7.«Êì¸Ê ¦Àñ¦À¡¸õ Å¢ÕõÒ¾ø  - Having thought of sexual 
intercourse always 
8.Á¢Ìó¾ ÀðÊÉ¢     -   Starvation for longtime 
9.¸Î¨ÁÂ¡É ¦ÅöÂ¢Ä¢ø «¾¢¸õ ¿¼ò¾Ä¢É¡ø ²üÀÎõ À¡¾í¸ª¢ø ÝÎ- Walking 
without footwear 
10.¸¡ÃÁ¡É ¦À¡Õð¸û, ¯ôÒ, ÐÅ÷ôÒ, ¨¸ôÒ Í¨ÅÔ¨¼Â ¦À¡Õð¸¨ª «¾¢¸õ 
Òº¢ò¾ø 
- Increased intake of spicy food, salty food, astringents and bitter tasty foods.  
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II. ACCORDING TO AGASTHIYAR GUNAVAGADAM 
 
      " §¸ª¼¡ À¢Ã§Á¸ ¯ûÀò¾¢ ¾ý¨É 
            ¦¸½¢¾Ó¼ý ¦º¡øÖ¸¢ý§Èý ¿ýÈ¡öì §¸Ù 
         
¿ý¨ÁÔ¼ý §Á¡¸Ó¼ý ÀðÊÉ¢Â¡Öõ 
  
À¡Æ¼¡ «¾¢¸Á¡ö Òº¢ôÀ¾¡§Ä 
 À¡í¸¡É À¢Ã§Á¸ó §¾¡Ïõ À¡§Ã" 
                                -«¸ò¾¢Â÷ Ì½Å¡¸¼õ 
 
1. Repeated sexual act 
2. Lustfulness with starvation  
3. Restraining the ejaculation of semen during sexual intercourse 
4. High intake of salty, salty and astringent foods.  
 
III ACCORDING TO THIRUMOOLAR KARUKKIDAI VAITHIYAM 600 
"«ýÉõ À¢Èó¾Ð «¨ÉòÐ Å¢¨¾Â¢Öõ 
ÁýÉ¢Â ¦Åð¨¼ Á¸¡º£¾õ ­ÃñÊÉ¡ø 
ÀýÉ¢ «È¢ó¾¢¨¾ô À¡÷À¡÷ ¦ÀÃ¢§Â¡÷¸û 
¸ýÉ¢ ÁÂì¸ò¾¡ø ¸ñÊÎõ §Á¸§Á" 
  
 ¬õÁ¢ªò¨¾ô ÀÕÅÁ¾¢ø §Á¡¸¢òÐõ  
 §À¡¸ó¾¢Éï ¦ºöÂ¢ü Ò¸ú Áó¾ò§¾ ÜÊø 
 Å¡¸ô Àº¢Â¡ø ÅÆí¸ï ¨º§Â¡¸§Á" 
        
 ³Â¡ «Á¢÷¾õ «¼ì¸¢ì ¸É§ÄÚõ 
 ¦ÁöÂ¡¸ Å¢óÐ Å¢Æô Òñ½¡Ìõ 
 ¨ÁÂ¡É §Á¸õ ÅªÕí ¸¢Ãó¾¢§Â" 
                          -¾¢ÕãÄ÷ ¸Õì¸¢¨¼ ¨Åò¾¢Âõ 600 
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Performing sexual act in the adolescent age,during digestive disturbances and 
doing improper practice of kundalini yoga.  
 
IV.ACCORDING TO AGASTHIYAR VAIDDHIYA KAAVIYAM 1500  
 
"§Á¸í¸û À¢ÈóÐ ¿¢ýÈ Å¢¾í¸¨ª Å¢ªõÀì §¸Ù 
¬¸í¸û ­¸úó¾§À¡Ð «ôÀ§É ¾¢ÉÓõ ¦ºýÈ 
§À¡¸í¸û ¦ºöÔõ §À¡Ðõ Ò¸úÁó¾õ ÜðÎõ §À¡Ðõ 
À¡¸í¸û Àº¢ÂëÎõ ÀÕÌï ¨º§Â¡¸ó¾§É 
¨º§Â¡¸ï ¦ºöÔõ §À¡Ðõ ¾É¢¿¢ýÈ ÍÆ¢§Â§Â¡Î 
¨ÁÂ§Å¡ «Ó÷¾ó¾ý¨É «¼ì¸¢§Â «Éø¾¡ý ¦¸¡ûÙõ 
¦ÁöÂ¼¡ Å¢óÐ¸¡½¢ø Å¢ÆÅ¢Æô ÒñÏó¾¡Û 
¨ÁÂ¼¡ §Á¸ò¾¡§Ä Åª÷ó¾Ð ¸¢Ãó¾¢À¡§Ã" 
 
-«¸ò¾¢Â÷ ¨Åò¾¢Âõ 1500 
 
Insulting or reticulating the sacred books, excessive sexual act, having sex during 
indigestion & hungry and suppressing the ejaculation of semen during sexual act cause 
Meganoi.  
  
v. According to T.V.SAMBASIVAM PILLAI the chief causes of Kirumi Yoni Rogam 
is  
o Veneral disorder 
o Improper dietary habits 
o Intemperate habits 
o Conceptional defects 
o Any accidental happening 
o Prostitution 
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VI. According to Prof.Dr.Venugopal in his text magalir maruthuvam (Page No.124) 
             1.Due to physiological factors 
 2.Altered sexual indulgence. 
 
 NOI ENN (CLASSIFICATION): 
 Yugimuni classified penkuri roga padalam into 20 types. They are as follows:[1] 
 Å¡¾ §Â¡É¢ §Ã¡¸õ 
 À¢ò¾ §Â¡É¢ §Ã¡¸õ 
 ¸À §Â¡É¢ §Ã¡¸õ 
 ÌÕ¾¢ §Â¡É¢ §Ã¡¸õ 
 ÌÕ¾¢º£ú §Â¡É¢ §Ã¡¸õ  
 ÅÄ¢ §Â¡É¢ §Ã¡¸õ 
 ¦¸¡¾¢ôÒ §Â¡É¢ §Ã¡¸õ 
 Ý¨Ä §Â¡É¢ §Ã¡¸õ 
 Íð¸ §Â¡É¢ §Ã¡¸õ 
 §¸¡¨Æ §Â¡É¢ §Ã¡¸õ 
 º¢ÅôÒ §Â¡É¢ §Ã¡¸õ 
 ÅÊ §Â¡É¢ §Ã¡¸õ 
 Á¸¡ §Â¡É¢ §Ã¡¸õ 
  
 «¾¢ºÃ½ §Â¡É¢ §Ã¡¸õ 
 àÄ¢¾ §Â¡É¢ §Ã¡¸õ 
 âôÒì¸¡Ä §Â¡É¢ §Ã¡¸õ 
 ¸¢ÕÁ¢ §Â¡É¢ §Ã¡¸õ 
 ¾¡Á¨Ãì¸¡ö §Â¡É¢ §Ã¡¸õ 
 Å¢ÀÃ£¾ôÒ½§Ã¡É¢ §Ã¡¸õ 
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MUKKUTRA IYAL (PATHOLOGY): 
          Certain extrinsic and intrinsic factors alter the equilibrium of tridosha and produces 
the disease. Kirumi Yoni Rogam is mainly due to aggrevated pitha humour which are 
evident from the quote mentioned below, 
                   "À¸÷À¢ò¾ Å¢ó¨¾ÂÄ¡Ð §Á¸õ Å¡Ã¡Ð"[7] 
                                                     - §¾¨ÃÂ÷ (ref. Noi Nadal Noimuthal Nadal part I) 
It denotes that alteration of pitham causes mega diseases. Altered pitham affects 
abanan and viyanan. 
 Affected abanan alters the theyu pootham which leads to burning sensation in the 
urethra, burning micturition, purulent discharge in the urethra, low back pain and 
constipation. 
 Affected viyanan alters akaya pootham which leads to loss of appetite, fatigue, 
pain all over the body, emaciation, altered sleep rhythm and mental tiredness.       
 
UDAL KATTUKAL:  
                These are seven basic principles which constitute the entire body described in 
Siddha text.  
 
SEVEN PHYSICAL CONSTITUENTS OF THE BODY   
1. Saaram - This gives mental and physical perseverance.  
2. Senneer       -  Imparts colour to the body and nourishes the body  
3. Oon              -  It gives shape to the body according to the physical  
                                         activity and plasters the skeleton to give the body a             
                                          plumpy appearance.  
4. Kozhuppu    -  It lubricates the joints and other parts of the body for    
                                      a. smooth functioning.   
5. Enbu           -  Supports the frame and responsible for the postures and    
                                     a. movements of the body.  
6. Moolai        -  It occupies the medulla of the bones and gives strength  
                                        and softness to them.  
7. Sukkilam/Suronitham   -  It is responsible for reproduction. 
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In case of Kirumi Yoni Rogam  saram, senneer, oon, kozhuppu, enbu, suronitham are 
affected.  
 Saram    -   Loss of apetite, fatigue.  
 Senneer   -   Weakness of the body,anemia.  
 Oon     -   low Back pain, 
 Kozhupppu  -   Emaciation  
 Enbu    -   low back pain    
 Suronitham   -  Yellowish or curdy vaginal discharge. 
 
PINIYARI MURAIMAI: [7] 
Pini means the disease which affect the body.Any interruption of the normal 
functions of any body part, organ or system.  
  Ari means identify. Muraimai means Rules  
Piniyari muraimai is the method of diagnosing the disease in affected people. It is 
based upon the following aspects:   
1. Poriyalarithal  
2. Pulanaalarithal  
3. Vinaathal  
4. Envagaithervugal  
5. Naadiparitchai   
            The above principles correspond to the methodology of inspection, palpation and 
interrogation of modern medicine.   
 
Poriyalarithal : 
- are the five organs of perception namely, 
1.Nose 
2.Tongue 
3.Eyes 
4.Ears and  
5.Skin 
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Pulanarithal: 
 
1.Smell 
2.Taste 
3.Vision 
4.Hearing 
5.Touch respectively. 
the patient. 
 
Vinathal:  
           It is a procedure for gathering information about the patients name, 
age,occupation, nativity, socio economic status, family history, dietary habits, allergic 
factors, period of suffering from the complaints, history of previous episodes, relevant 
the patient is not in a position to speak or if the patient is child.  
In Kirumi Yoni Rogam vinathal is very much useful for Piniyarimuraimai, 
occupation, family history, dietary haits, proper treatment and socio economic status  are 
very important for Kirumi Yoni Rogam. 
 
Envagai thervugal: [7] 
Eight different kinds of tests to be applied or attended by a physician before 
arriving 
a correct diagnosis. These are also called Attavitha Paritchai or  Attasthanna Parikshai. 
                   
        " ¿¡Ê ÀÃ¢ºõ ¿¡ ¿¢Èõ ¦Á¡Æ¢ Å¢Æ¢  
                
 
According to Theraiyar 
   
           
          ­ÕÁÄõ ¨¸ìÌÈ¢" 
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According to Agasthiyar Guna Vagadam: 
"¾Ã½¢Ôûª Å¢Â¡¾¢¾ý¨É Âð¼¡í¸ò¾¡ø 
¾¡ÉÈ¢Â §ÅñÎÅÐ Â¡§¾¡ ¦ÅýÉ¢ø 
¾¢Ã½¢Â§¾¡÷ ¿¡Ê ¸ñ¸û ºò¾ò§¾¡Î 
§¾¸ò¾¢ÉÐ ÀÃ¢ºõ ÅÕ½õ ¿¡ìÌ 
Â¢Ã½ ÁÄ ãò¾¢Ã¡ Á¢¨Å¸ ¦ªðÎõ 
Ã½Õª¡ø ¦ÀÃ¢§Â¡÷¸û À¡¾õ §À¡üÈ¢ô 
ÀñÒ ¾ÅÈ¡Áø ÀñÊ¾ï ¦ºöÅ£§Ã" 
 
Noi Nadal Noi Muthal Nadal Part-I, Page:129 
1. Naadi (Pulse)  
2. Sparisam (Palpation)  
3. Naa (Tongue examination)  
4. Niram (Colour of the body)  
5. Mozhi (Speech)  
6. Vizhi (Eye Examination)  
7. Malam (Motion Examination)  
8. Moothiram (Urine examination)   
 
1.Naadi:  
            Naadi is the vital force and the main diagnostic scale in the Siddha system.Any 
change in the three doshas are best diagnosed by feeling the naadi.Naadi  is responsible 
for the existence of life and can be felt one inch below the wrist on the radial side by 
means of palapation with the tips of index, middle and ring finger corresponding to 
Vatham ,Pitham and Kabam.Normally these 3 vital forces exist In the ratio 1:1/2:1/4. 
Derrangement of this ratio leads to various disease entities. 
In  Kirumi Yoni Rogam the following Naadi nadai are seen commonly, 
 1.Pitham 
 2.Vatham 
 3.Vathapitham 
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In sathaga naadi padal:[7] 
"¯Ú¾¢Ôûª À¢ò¾ÁÐ §¾¡ýÈ¢ø ¦ÅôÒ 
¯ðÉÅ¡ö Åò¾¢ÍÃ Á¾¢º¡Ãí¸û 
ÁÈ¾¢Ô¼ý ¸¢Ú¸¢ÚôÒô ¨Àò¾¢Â §Ã¡¸õ 
Åª÷§º¡¨¸ ÂÆ¦ÄÃ¢× ¸¡ó¾ø ¨¸ôÒ 
­Õ¾Âò¾¢ü ¸Äì¸ÁÐ ÁÈôÒ ¾¡¸õ 
±Øí¸É× §ÀÂ¨½× ÁÂì¸ ã÷î¨º 
º¢È¢Ð ¦ÀÕõÀ¡Î Ãò¾ À¢Ã§Á¸í¸û 
§º÷óÐ ¦ÅÌ À¢½¢ ÀÄ×ï º¢ÈìÌò ¾¡§É" 
 
Due to derangement of Vatha naadi, 
"Å¡¾¦ÁÛõ ¿¡ÊÂÐ§¾¡ýÈ¢ø.............................. 
       ......................¾óÐ§Á¸õ" 
 
2. Sparisam:   
                    The following points are elicited by Sparisam , the temperature of skin (Heat 
or cold) , smoothness, roughness, softness, sweat , dryness , sensation . 
 
In Kirumi Yoni Rogam along with general sparism aspects ,it is especially used 
for per vaginal examination. 
 
3. Naa:  
  By inspecting the tongue its colour, coating, ulcer, deviation, roughness, silky soft 
& any abnormality of the tongue is noted. 
In Kirumi Yoni Rogam the tongue will be dry and coated denotes less appetite. If 
anemia is present the tongue will pallor.       
 
4. Niram: 
It denotes the colour of skin, palm etc. The colour of vaginal discharge expel out 
represents the type of kuttram.  
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5. Mozhi: 
   It constitutes high or low pithched voice, slurring, incoherent speech, nasal 
speech, hoarseness of voice. 
In Kirumi Yoni Rogam the tone and speech will be in  medium mode. 
 
6. Vizhi: 
       Both motor and sensory disturbances of eye are noted. Burning sensation of 
eyes,lacrimation, irritation, colour are noted. 
 
In Kirumi Yoni Rogam  burning sensation of eyes is present.  
 
7. Malam Faeces) :  
             In the examination of Malam, Niram (colour ) ,Nurai (froth), Erugal 
(Solid).,Elagal (Semisolid or liquid), quantity (increased or decreased) smell can be noted 
other examination like diarrhea, presence of blood, mucus, undigested matter in the stools 
and odour can also be studied.   
 
8. Moothiram:  (Urine)  
            In the examinantion of urine, colour, odour, quantity of urine, the presence of 
froth, deposits, blood, pus, inorganic sediments, abnormal constituents such as sugar, 
 
          The diagnosis is usually arrived  by methods of urine examinations called 
  1.NEERKURI 
2.NEIKURI.   
 
Collection of Urine: 
"«ÕóÐÁ¡È¢Ã¾Óõ «Å¢§¼¡ ¾Á¾ö 
 «ì¸ø «Ä÷¾ø «¸¡Äçý ¾Å¢÷ó¾úü 
 ÌüÈªÅÕó¾¢ ¯Èí¸¢ ¨Å¸¨È 
 ¬Êì ¸Äºò ¾¡Å¢§Â ¸¡Ð¦Àö 
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 ¦¾¡Õ ãÜ÷ò¾ì ¸¨ÄøÌðÀÎ ¿£Ã¢ý 
 ¿¢ÈìÌÈ¢ ¦¿öìÌÈ¢ ¿¢ÕÁ¢ò¾ø ¸¼§É 
                          -§¾¨ÃÂ÷ ¿£÷ìÌÈ¢ ¦¿öìÌÈ¢ áø[8] 
Prior to the day of urine examination, the patient should be advised to take a 
balanced diet and should have good rest.The first voided urine of the patient is collected 
in a glass container. The colour, volume, froth, smell, specific gravity and sedimentation 
is noted. A drop of Gingelly oil is added into the container without any disturbance  and 
the tendency to spread is examined with in 1 ½ hrs.   
 
i.Neerkuri: 
"Åó¾ ¿£÷ ¸Ã¢ ±¨¼ Á½õ Ñ¨Ã ±ïº¦Äý 
 ¨Èó¾¢Â ÖªÅ¨Å Â¨È¸Ð Ó¨È§Â" 
 
In Neerkuri, Niram, Edai, Manam, Nurai and Enjal of the urine voided is noted.  
 
                            «ÕôÀ¡ ÓüÈ¡÷ì ¸ùÅ¢¾¢ Å¢Äì§¸" 
The following parameters in the urine should be examined.  
Niram   :  It indicates the colour of the urine voided.  
Edai    :  It indicates the specific gravity of urine (increased or decreased  
                             quantity)  
Manam :  It indicates the smell of urine voided.  
Nurai    :  It indicates the frothy nature of urine voided  
Enjal    :  It indicates the quantity of urine   
In addition frequency of micturition, burning micturition, any sedimentation and 
any associated discharge can be find out. 
In  Kirumi Yoni Rogam burning and painful micturition associated with purulent 
discharge. 
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ii.Neikuri: 
               A drop of Gingelly oil is dropped into a wide mouthed vessel containing the 
urine to be tested and kept it under the sunlight in a air free place. The variations of the 
three thathus in disease can be diagnosed by the behaviour of Gingelly oil on the surface 
of urine.    
 
Observation  
I. Vathaneer:        
"«Ã¦ÅÉ ¿£ñÊý «·§¾ Å¡¾õ" 
The drop of oil lengthening like a snake indicates Vatham (Vali)   
 
II. Pithaneer: 
       "¬Æ¢§À¡ü ÀÃÅ¢ý «·¦¾ À¢ò¾õ" 
The drop of oil spreading like a ring it indicates Pitham (Azhal)    
 
III. Kabaneer: 
       "Óò¦¾¡òÐ ¿¢ü¸¢ý ¦Á¡Æ¢Å¦¾ý ¸À§Á" 
 If the oil drops assumes a pearl shape it is presumed to be Kabham(Iyam).  
 
IV. Thonthaneer: 
"«ÃÅ¢Ä¡Æ¢Ôõ ¬Æ¢Â¢ø «Ã×õ «ÃÅ¢ø ÓòÐõ ¬Æ¢Â¢øÓòÐõ 
 §¾¡üÈ¢ø ¦¾¡ó¾ §¾¡¼í ¸ª¡§Á" 
 
When the drop of oil shows two shapes enclosed within one another it indicates 
thonthaneer. 
In Kirumi Yoni Rogam the neikuri spreads like a ring. By the careful examination 
of the urine with gingelly oil, the physicians can know whether the disease is curable or 
not. For this purpose Siddhars have explained various spreading tendencies of oil on urine 
surface to define the prognosis of the disease. 
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Noi Kanippu vivadham 
1) ¸Õô¨À ¸ØóÐ ¾¡À¢¾õ:[1] 
          ÌÎõÀ¡ ¸ðÎôÀ¡ðÊü¸¡É ¯§Ä¡¸í¸ª¢É¡§Ä¡ ­Ã¡º¡Â½ô 
¦À¡Õû¸ª¢É¡§Ä¡ ¦ºö¾ ¸ÕÅ¢¸¨ª ¿£Êò¾ ¸¡Äõ ¯À§Â¡¸ôÀÎò¾¢É¡Öõ 
¸Õô¨À ¸ØóÐ ¾¡À¢¾õ ¯ñ¼¡Ìõ. 
             By the use of contraceptive devices for longtime, inflammation occurs. 
 
ÌÈ¢Ì½õ: 
 §Â¡É¢¸º¢× 
 ÒîºôÀ¡Ä¢¨¸ ¦À¡ÕòÐ ÅÄ¢ 
 ÌÚìÌ ÅÄ¢ 
 ¿£÷ «Õ¸ø 
 «Êì¸Êº¢Ú¿£÷ ¸Æ¢× 
Vaginal secretion, Low back pain, Dysuria, Incontinence of urine, Polyuria 
 
2)º¢¨Éô¨À ¾¡À¢¾õ: 
 
       À¢ÍÀ¢Íò¾ ºª¢ §À¡ýÈ ¸º¢× 
«ÊÅÂ¢üÈ¢ø ¸Î¸Îò¾ ÅÄ¢ 
ÁÄîº¢ì¸ø ¯¼ü¸¡í¨¸ ¯ÂÚõ 
¿¡ìÌ ÅÈñÎ Á¡× ÀÊó¾¢ÕìÌõ 
âôÒ ¸¡Äí¸ª¢ø ¦ÀÕõÀ¡Î 
 
Mucous vaginal discharge, Lower abdominal pain, Constipation, Increased body 
temperature,Coated tongue, Mennorhagia. 
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Maruthuvam (treatment) :[7] 
"¯üÈ¡Éª×õ À¢½¢Âª×í ¸¡ÄÓõ 
 ¸üÈ¡ý ¸Õ¾¢î ¦ºÂø" 
-ÌÈû 
 
The treatment should be based on the age and body built of the patient, the 
severity of the disease and the period of the ailment. Siddha system of medicine besides 
treating the diseases  and  improves the body condition. This is said as follows:   
a. Kaappu (Prevention)  
b. Neekkam (Treatment)  
c. Niraivu (Restoration of well being)   
 
a. Kaappu (Prevention ): 
          Siddha system has unequivocally stated that even during the time of 
conception,some defects creep into the fertilized embryo, which forms certain diseases. 
Those diseases may be cured not only by medicine but by teaching the following habits. 
 Teaching good moral habits 
 Avoid excessive sex indulgence 
 Aviod pre and extra marital sex 
 Avoid sex after taking oil bath and curd rice 
 Avoid stress and anxiety 
 Always have good mental thoughts by doing meditation 
 Avoid the use of un hygienic undergarments 
 Always wash the undergarments in a soap plus disinfectant solution 
 Avoid urinary infection by taking large amount of water 
 Avoid increased intake of spicy,sour and salty foods 
 Taking oil bath regularly 
 Taking laxative once in 6 months 
 Always do yoga practice and pranayamam according to their physical and mental 
conditions. 
  Medicine: Padigara parpam 130mg twice a day after food with ghee for 24 days. 
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b. Neekkam  (Treatment):  
       According to Noi Nadal and Noi muthal Nadal a good physician should know the 
deranged kuttram and treat the patients on the basis of altered kuttram. 
"ÓôÀ¢½¢ ÁÕÅ¢ ÓÈ¢×¦¸¡û ÌÈ¢ô¨À 
¾ôÀ¡¾È¢Ôõ ¾ý¨ÁÔõ Å¡¾Å¢ò¾¨ÅÂô À¢Ã¢¨ÅÔ Á¨Å¾¡õ 
²È¢Â¢Èí¸¢ ­¨½óÐ ¸ÄóÐ 
Á¡È¢ Á¡È¢ ÅÕóÐ ¦ºö¨¸Â¡ü À¢½¢ 
§¿÷¨ÁÂÈ¢óÐ ¿£ðÎ ÁÕó§¾ 
º£Ã¢Â¾¡ ¦ÁÉî ¦ºôÒÅ÷ º¢ò¾§Ã" 
- Noi Nadal and Noi muthal Nadal Part I 
The aim of treatment is based on  
 Bringing of tridosham to normal 
 To treat the disease according to its symptoms by internal 
 
For normalizing tridosham: 
 
ÅÁÉò¾¡ø À¢ò¾õ ¾¡Øõ 
¿º¢Â «ïºÉò¾¡ø ¸Àõ ¾¡Øõ" 
 
purgatives are given according to patients tolerance to drug and also the severity 
of the disease should be assessed. 
 
 
 In Kirumi Yoni Rogam pitham is altered as well as vatham. So laxative is 
administered on the first day or before starting the specific treatment. 
 
Pathiyam: 
 
          During the course of the treatment ,the patient is advised to follow certain 
precautions regarding diet and physical activities. This form of medical advice in Siddha 
system of m
of medicine. 
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"Àò¾¢Âò¾¢É¡¦Ä ÀÄÛñ¼¡Ìõ ÁÕóÐ 
 Àò¾¢Âí¸û §À¡É¡ø ÀÄý§À¡Ìõ-Àò¾¢Âò¾¢ø 
 Àò¾¢Â§Á ¦ÅüÈ¢ ¾Õõ ÀñÊ¾Õì ¸¡¾Ä¢É¡¾ 
 Àò¾¢Â§Á ¯ò¾¢¦ÂÉ À¡÷" 
Pathiyam has been classified into itchapathiyam and kadum pathiyam 
 
Itchapathiyam: 
"¸Î¸¢¿üÈ¢Äò ¦¾ñ¦½öÜúô À¡ñ¼í¸û ¸¼¨Ä 
 ÅÊÅ¾¡¸¢Â ¦¾íÌÁ¡ ÅÕì¨¸¿ü ¸¡Âõ 
 ÁÊÅ¢Ä¡¾¦Åû Ùûª¢¦¸¡û Ò¨¸Â¢¨Ä ÁÐ¦Àñ 
 ­¼ÐÀ¡¸§Ä¡ ¼¸ò¾¢¿£  
 
Kadum pathiyam: 
"¸Î¨Á ¦ÂýÈ¢Î Àò¾¢Âõ ãÅ÷ÅÚò Ðñ¼ø 
 ¬¨¼Å¢Ä¡ ÁÚÀò¾¢ò ÐÅ÷ ÅÚò¾Õò¾ø 
 ¦¸¡Î¨Á ¦ºöÒª¢ ¾¨ÉîÍðÎ ÜðÊ¼ ÄýÈ¢ô 
 ÀÊÂ¢ø ¸ò¾¢Ã¢ º¢ìÌ¨Ã À¢ïº¢¨Éô ÀÕ¸ø" 
 
Pathiyam (diet) for Pitha disease: 
Pathiyam for pitha disease as mentioned in patharthaguna chindamani is as follows:  
      "¦¸¡õÁðÊ Å¡¨ÆôÀýÉ¡í ¦¸¡Ùò¾¢Â ¸Ã¢Â¢ §¿¡§¼ 
 Å¢õÁ¢Â ¾ñ½£÷Å¢ð¼¡ý §Å¦ÃÛí ¸¢ÆíÌ º¡ó¾ï 
 ¦ºõ¨Á§º÷ ¦¿øÄ¢Óûª¢ §ºÕÁ¢ø ÁÕó¦¾øÄ¡§Á 
 ¸õÁ¢Â Á¢ò¾ò¾¢üÌ ¸¡Ä¦Äý §È¡Ð Å¡§Ã" 
 
c.Niraivu (Restoration of well being): 
1. Reassurance of recovery were given to every patients. 
2. Every patient were advised to follow strict diet restrictions,good moral behaviour. 
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DIET AND ADVICE: 
The following diet to be taken: 
  Drink adequate water 
 Leafy greens & vegetables 
  
 Onion 
 Ginger 
 Steamed vegetables & vegetable salads 
 Riped bananas 
 Lemon or orange juice 
 Apple 
 Black plums 
 Pears 
 Gooseberry 
 Dates 
 Fig fruit 
 Pome granate 
 Grapes 
 Guava 
 Whole wheat 
 Brown rice 
 Milk 
 Butter milk 
 Ghee 
 Fenugreek 
 Coriander seeds 
 Cumin seeds 
 
The following food should be avoided: 
 Bitter gourd                                                         
 Chicken  
 Meat     
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 Coconut 
 Jack fruit 
 Asafoetida 
 Mango                            
 Brinjal   
 Sesbanian leaves 
 Mustard 
 Sesame                                                                 
 Tamarind 
 Eggs 
 Mushrooms 
 Bread 
 Sweets 
 White sugar 
 Tea 
 Coffee 
 Preserved cool drinks 
 Oily  & fried foods 
 Sour foods 
 
AVOID: 
 Tobacco 
 Alcohol  
 Excessive lust                     
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                              REVIEW OF LITERATURES 
A. MODERN ASPECT     
             ANATOMY OF THE FEMALE REPRODUCTIVE SYSTEM[14] 
 
The female reproductive system can be divided into the external and internal 
genitalia. The external genital organs are vulva and the vagina. The internal genital 
organs are uterus, cervix, fallopian tubes, ovaries and other supporting structures. 
The vulva is an ill-defined area, which comprises the following structures. 
 The Mons pubis     
 The Labia majora 
 The Labia minora 
 The Clitoris 
 The Vestibule 
 The External meatus 
  
 The Hymen, surrounding the orifice 
 The Navicular fossa  
 The Fourchette 
 
 The external genital organs have three main functions: 
 Enabling sperm to enter the body 
 Protecting the internal genital organs from infectious organisms 
 Providing sexual pleasure 
 
1.The Mons pubis: 
The mons pubis is a rounded mound of fatty tissue that covers the pubic bone. 
During puberty, it becomes covered with hair. The mons pubis contains oil-secreting 
(sebaceous) glands that release substances that are involved in sexual attraction 
(pheromones). 
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2.The Labia Majora: 
The labia majora (literally, large lips) are relatively large, fleshy folds of tissue 
that enclose and protect the other external genital organs. They are comparable to the 
scrotum in males. The labia majora contain sweat and sebaceous glands, which produce 
lubricating secretions. During puberty, hair appears on the labia majora. 
 
3.The Labia Minora 
The labia minora (literally, small lips) can be very small or up to 2 inches wide. 
The labia minora lie just inside the labia majora and surround the openings to the vagina 
and urethra. A rich supply of blood vessels gives the labia minora a pink color. During 
sexual stimulation, these blood vessels become engorged with blood, causing the labia 
minora to swell and become more sensitive to stimulation. 
External Female Genital Organs 
                                             
 
4.Clitoris: 
The clitoris is an erectile structure found beneath the anterior joining of the labia 
minora. Its width in an adult female is approximately 1 cm, with an average length of 
1.5 2.0 cm. The clitoris is made up of 2 crura, which attach to the periosteum of the 
ischiopubic rami. It is a very sensitive structure, analogous to the male penis. It is 
innervated by the dorsal nerve of the clitoris, a terminal branch of the pudendal nerve. 
 
5.Vestibule : 
 6. Urethra: 
Between the clitoris and the vaginal introitus (opening) is a triangular area known 
as the vestibule, which extends to the posterior fourchette. The vestibule is where the 
urethral (urinary) meatus is found, approximately 1 cm anterior to the vaginal orifice, and 
it also gives rise to the opening of the Skene glands bilaterally. The urethra is composed 
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of membranous connective tissue and links the urinary bladder to the vestibule externally. 
A female urethra ranges in length from 3.5 to 5.0 cm. 
 
7. Bartholin glands: 
  The greater vestibular (Bartholin) glands are  responsible for secreting lubrication 
to the vagina, with openings just outside the hymen, bilaterally, at the posterior aspect of 
the vagina. Each gland is small, similar in shape to a kidney bean. 
 
8.Hymen: 
The hymen is a thin membrane found at the entrance to the vaginal orifice. Often, 
this membrane is perforated before the onset of menstruation, allowing flow of menses. 
The hymen varies greatly in shape. 
 
INTERNAL GENITALIA 
Vagina: 
The vagina extends from the vulva externally to the uterine cervix internally. It is 
located within the pelvis, anterior to the rectum and posterior to the urinary bladder. The 
vagina lies at a 90º angle in relation to the uterus. The vagina is held in place by 
endopelvic fascia and ligaments (see the image below). 
The vagina is lined by rugae, which are situated in folds throughout. These allow 
easy distention, especially during child bearing. The structure of the vagina is a network 
of connective, membranous, and erectile tissues. 
The pelvic diaphragm, the sphincter urethrae and transverse peroneus muscles, 
and the perineal membrane support the vagina. The sphincter urethrae and the transverse 
peroneus are innervated by perineal branches of the pudendal nerve. The pelvic 
diaphragm primarily refers to the levator ani and the coccygeus and is innervated by 
branches of sacral nerves S2-S4. 
The vascular supply to the vagina is primarily from the vaginal artery, a branch of 
the anterior division of the internal iliac artery. Several of these arteries may be found on 
either side of the pelvis to richly supply the vagina. 
The nerve supply to the vagina is primarily from the autonomic nervous system. 
Sensory fibers to the lower vagina arise from the pudendal nerve, and pain fibers are from 
sacral nerve roots. Lymphatic drainage of the vagina is generally to the external iliac 
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nodes (upper third of the vagina), the common and internal iliac nodes (middle third), and 
the superficial inguinal nodes (lower third). 
 
The vaginal secretion: 
 The vaginal secretion is small in amount in healthy women and consists of white 
coagulated material. The top layers are rich in glycogen and some of these squamous cells 
are shed &acted on by the gram positive Doderlein bacilli present in the vagina, 
converting this glycogen into lactic acid. This action is responsible for maintaining the pH 
of the vagina around 4.5 and preventing the growth of pathogenic organisms. 
 Because of this protective function,the doderline bacillus is considered as vaginal 
policeman. However with menopause and also prior to puberty ,the vaginal mucosa is 
thin ,devoid of glycogen due to the absence of estrogenic stimulus, hence the pH of the 
vagina is alkaline. 
The vaginal pool contains desquamated epithelial cells from the cervix, uterus and 
vagina. These cells are aspirated and the smears are papanicolaou-stained for assessment 
of ovarian function & also for the early detection of genital cancer especially, of the 
cervix.    
 
Normal Vaginal Flora: 
Resident vaginal flora consists of a combination of both aerobic and anaerobic 
organisms. The microflora of normal vaginal secretions is characterized by a 
predominance of lactobacilli, primarily acidophilic lactobacilli. Usually, an additional 5 
to 15 bacterial species are also normally cultured from the vagina G. vaginalis can be 
found in  >50% of normal, healthy women. 
Common aerobic facultative organisms found include lactobacilli, staphylococcus 
epidermis, streptococci and G. Vaginalis. The anaerobic organism commonly found 
includes Bacteroides species, B.bivius and Peptostreptococcus. 
Mycoplasma hominis can be found in 20% to 50% and Ureaplasma urealyticum 
can be found in 50% to 70% of sexually active women. In women with normal vaginal 
flora, lactobacillus species account for >95% of the total organisms present.  
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Uterus: 
The uterus is the inverted pear-shaped female reproductive organ that lies in the 
midline of the body, within the pelvis between the bladder and the rectum. It is thick-
walled and muscular, with a lining that, during reproductive years, changes in response to 
 
The uterus can be divided into 2 parts: the most inferior aspect is the cervix, and 
the bulk of the organ is called the body of the uterus (corpus uteri). Between these 2 is the 
isthmus, a short area of constriction. 
The body of the uterus is globe-shaped and is typically situated in an anteverted 
position, at a 90º angle to the vagina. The upper aspect of the body is dome-shaped and is 
called the fundus; it is typically the most muscular part of the uterus. The body of the 
uterus is responsible for holding a pregnancy, and strong uterine wall contractions help to 
expel the fetus during labor and delivery. 
The average weight of a nonpregnant, nulliparous uterus is approximately 40-50 
g. A multiparous uterus may weigh slightly more than this, with an upper limit of 
approximately 110 g. A menopausal uterus is small and atrophied and typically weighs 
much less. 
The cavity of the uterus is flattened and triangular. The uterine tubes enter the 
uterine cavity bilaterally in the superolateral portion of the cavity. 
The uterus is connected to its surrounding structures by a series of ligaments and 
connective tissue. The pelvic peritoneum is attached to the body and the cervix as the 
broad ligament, reflecting onto the bladder. The broad ligament attaches the uterus to the 
lateral pelvic side walls. Within the broad base of the broad ligament, between its anterior 
and posterior laminae, connective tissue strands associated with the uterine and vaginal 
vessels help to support the uterus and vagina. Together, these strands are referred to as the 
cardinal ligament. 
Rectouterine ligaments, lying within peritoneal folds, stretch posteriorly from the 
cervix to reach the sacrum. The round ligaments of the uterus are much denser structures 
and connect the uterus to the anterolateral abdominal wall at the deep inguinal ring. They 
lie within the anterior lamina of the broad ligament. Within the round ligament is the 
artery of Sampson, a small artery that must be ligated during hysterectomy. 
The vasculature of the uterus is derived from the uterine arteries and veins. The 
uterine vessels arise from the anterior division of the internal iliac, and branches of the 
uterine artery anastomose with the ovarian artery along the uterine tube. 
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The nerve supply and lymphatic drainage of the uterus are complex. Lymphatic 
drainage is primarily to the lateral aortic, pelvic, and iliac nodes that surround the iliac 
vessels. The nerve supply is attained through the sympathetic nervous system (by way of 
the hypogastric and ovarian plexuses) and the parasympathetic nervous system (by way of 
the pelvic splanchnic nerves from the second through fourth sacral nerves). 
 
Cervix: 
The cervix is the inferior portion of the uterus, separating the body of the uterus 
from the vagina. The cervix is cylindrical in shape, with an endocervical canal located in 
the midline, allowing passage of semen into the uterus. The external opening into the 
vagina is termed the external os , and the internal opening into the endometrial cavity is 
termed the internal os. The internal os is the portion of a female cervix that dilates to 
allow delivery of the fetus during labor. The average length of the cervix is 3-5 cm. 
The vasculature is supplied by descending branches of the uterine artery, which 
the cervix is via the parasympathetic nervous system by way of the second through fourth 
sacral segments. Many pain nerve fibers run alongside these parasympathetics. Lymphatic 
drainage of the cervix is complex. The obturator, common iliac, internal iliac, external 
iliac, and visceral parametrial nodes are the main drainage points. 
 
Uterine tubes: 
The uterine tubes (also referred to as oviducts or fallopian tubes) are uterine 
appendages located bilaterally at the superior portion of the cavity. Their primary 
function is to transport sperm toward the egg, which is released by the ovary, and then to 
allow passage of the fertilized egg back to the uterus for implantation. 
The uterine tubes exit the uterus through an area known as the cornua and form a 
connection between the endometrial and peritoneal cavities. Each tube is approximately 
10 cm in length and 1 cm in diameter and is situated within a portion of the broad 
ligament called the mesosalpinx. The distal portion of the uterine tube ends in an 
orientation encircling the ovary. 
The uterine tube has 3 parts. The first segment, closest to the uterus, is called the 
isthmus. The second segment is the ampulla, which becomes more dilated in diameter and 
is the typical place of fertilization. The final segment, furthest from the uterus, is the 
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infundibulum. The infundibulum gives rise to the fimbriae, fingerlike projections that are 
responsible for catching the egg that is released by the ovary. 
The arterial supply to the uterine tubes is from branches of the uterine and ovarian 
arteries, small vessels that are located within the mesosalpinx. The nerve supply to the 
uterine tubes is via both sympathetic and parasympathetic fibers. Sensory fibers run from 
thoracic segments 11-12 and lumbar segment 1. Lymphatic drainage of the uterine tubes 
is through the iliac and aortic nodes. 
 
Ovaries: 
The ovaries are paired organs located on either side of the uterus within the 
mesovarium portion of the broad ligament below the uterine tubes. The ovaries are 
responsible for housing and releasing the ova, or eggs, necessary for reproduction. At 
birth, a female has approximately 1-2 million eggs, but only 300 of these eggs ever 
mature and are released for the purpose of fertilization. 
The ovaries are small and oval-shaped, exhibit a grayish color, and have an 
uneven surface. The actual size 
status; the ovaries are approximately 3-5 cm in length during childbearing years and 
become much smaller and atrophic once menopause occurs. A cross-section of the ovary 
reveals many cystic structures that vary in size. These structures represent ovarian 
follicles at different stages of development and degeneration. 
Several ligaments support the ovary. The ovarian ligament connects the uterus and 
ovary. The posterior portion of the broad ligament forms the mesovarium, which supports 
the ovary and houses the vascular supply. The suspensory ligament of the ovary 
(infundibular pelvic ligament), a peritoneal fold overlying the ovarian vessels, attaches 
the ovary to the pelvic side wall. 
Blood supply to the ovary is via the ovarian artery; both right and left ovarian 
arteries originate directly from the descending aorta at the level of the L2 vertebra. The 
ovarian artery and vein enter and exit the ovary at the hilum. The left ovarian vein drains 
into the left renal vein, and the right ovarian vein empties directly into the inferior vena 
cava. 
Nerve supply to the ovaries run with the vasculature within the suspensory 
ligament of the ovary, entering the ovary at the hilum. Supply is through the ovarian, 
hypogastric, and aortic plexuses. Lymphatic drainage of the ovary is primarily to the 
lateral aortic nodes; however, the iliac nodes may also be involved. 
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                                         LEUCORRHEA[4] 
Leukorrhea  is a thick, whitish or yellowish vaginal discharge There are many 
causes of leukorrhea, the usual one being estrogen imbalance. The amount of discharge 
may increase due to vaginal infection or STDs, and also it may disappear and reappear 
from time to time, this discharge can keep occurring for years in which case it becomes 
more yellow and foul-smelling; it is usually a non-pathological symptom secondary 
to inflammatory conditions of vagina or cervix.  
Leukorrhea can be confirmed by finding >10 WBC under a microscope when 
examining vaginal fluid. 
Vaginal discharge is not abnormal, and causes of change in discharge include 
infection, malignancy, and hormonal changes. It sometimes occurs before a girl has her 
first period, and is considered a sign of puberty. 
 
                                        
Types of leucorrhea:[10] 
Abnormal vaginal discharge 
I.Non-infective 
II. Non-purulent, Non-offensive, Non-irritant 
a. Physiological   
b. Cervical cause 
c. Vaginal cause 
III. Infective 
           Purulent, offensive, irritant 
a. Specific 
b. Non-specific 
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IV.  Neoplastic  and  
V.Foreign body. 
 
NON-INFECTIVE LEUCORRHEA: 
Physiological cause: 
  The term "physiologic leukorrhea" is used to refer  leukorrhea due to estrogen 
stimulation. Leukorrhea may occur normally during pregnancy. This is caused by 
increased bloodflow to the vagina due to increased estrogen. Female infants may have 
leukorrhea for a short time after birth due to their in-uterine exposure to estrogen. 
 
Specific leucorrhea: 
 Any vaginal discharge which is frankly purulent and contains pus cells from 
which the causative organisms can be isolated and cultured should be considered as due 
to specific vaginal infection. 
Specific vaginitis comprises of : 
 Gonoccoccal 
 Trichomonal 
 Monilial 
 Chlamydial and  
 Bacterial vaginosis. 
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TRICHOMONIASIS[10] 
 
Trichomoniasis is a sexually transmitted infection caused by a one-celled 
protozoan, a type of tiny parasite that travels between people during sexual intercourse. 
The incubation period between exposure and infection is unknown, but it's thought to 
range from five to 28 days. 
Men who have trichomoniasis typically have no symptoms. Pregnant women who 
have trichomoniasis may be at higher risk of delivering their babies prematurely 
Many women and most men with trichomoniasis have no symptoms, at least not at 
first. 
  
Trichomoniasis signs and symptoms for women include: 
 A profuse and often foul-smelling vaginal discharge  which may be white, gray, 
yellow or green 
 Genital redness, burning and itching 
 Pain with urination or sexual intercourse. 
 
Risk factors include having: 
 Multiple sexual partners 
 A history of other sexually transmitted infections 
 A previous episode of trichomoniasis 
 Having sex without a condom. 
 
Pregnant women who have trichomoniasis may: 
 Deliver prematurely 
 Have a baby with a low birth weight 
 Transmit the infection to the baby as he or she passes through the birth canal 
Having trichomoniasis also appears to make it easier for women to become infected with 
HIV, the virus that causes AIDS. 
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LIFE CYCLE OF TRICHOMONIASIS 
 
 
DIAGNOSIS: 
 
There are three main ways to test for Trichomoniasis. 
 The first is known as saline microscopy. This is the most commonly used method and 
requires an endocervical, vaginal, or penile swab specimen for examination under a 
microscope. The presence of one or multiple trichomonads constitutes a positive 
result. This method is cheap but has a low sensitivity (60-70%) often due to an 
inadequate sample, resulting in false negatives. 
 Th
relatively cheap; however, sensitivity is still somewhat low (70-89%). 
 The third method includes the nucleic acid amplification tests (NAATs) which are 
more sensitive. These tests are more costly than microscopy and culture, and are 
highly sensitive (80-90%). 
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TREATMENT: 
Treatment for both pregnant and non-pregnant people is usually 
with metronidazole, by mouth once. Caution should be used in pregnancy, especially in 
the first trimester. Sexual partners, even if they have no symptoms, should also be treated. 
For 95-97% of cases, infection is resolved after one dose of 
metronidazole. Studies suggest that 4-5% of trichomonas cases are resistant to 
 Without treatment, 
trichomoniasis can persist for months to years in women, and is thought to improve 
without treatment in men. Women living with HIV infection have better cure rates if 
treated for 7 days rather than with one dose. 
 
PREVENTION: 
Use of male condoms may help prevent the spread of trichomoniasis,[15] although 
careful studies have never been done that focus on how to prevent this infection. Infection 
with Trichomoniasis through water is unlikely because Trichomonas vaginalis dies in 
water after 45 60 minutes, in thermal water after 30 minutes to 3 hours and 
in diluted urine after 5 6 hours.[16] 
Currently there are no routine standard screening requirements for the general 
U.S. population receiving family planning or STI testing.[17][18] The Centers for Disease 
Control and Prevention (CDC) recommends Trichomoniasis testing for females with 
vaginal discharge[19] and can be considered for females at higher risk for infection or of 
HIV-positive serostatus.[17] 
The advent of new, highly specific and sensitive trichomoniasis tests present 
opportunities for new screening protocols for both men and women.[17][20] Careful 
planning, discussion, and research are required to determine the cost-efficiency and most 
beneficial use of these new tests for the diagnosis and treatment of trichomoniasis in the 
U.S., which can lead to better prevention efforts.[17][20] 
A number of strategies have been found to improve follow-up for STI testing 
including email and text messaging as reminders of appointments.[21] 
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                                               MONELIASIS[11] 
 
Vulvovaginal candidiasis is the name often given to Candida albicans infection of 
the vagina associated with a dermatitis 
 Candida 
albicans infection. 
 
CAUSES: 
About 20% of non-pregnant women aged 15 to 55 harbour Candida albicans in 
the vagina. Most have no symptoms and it is harmless to them. Overgrowth of Candida 
albicans causes a heavy white curd-like vaginal discharge, a burning sensation in the 
vagina and vulva and/or an itchy rash on the vulva and surrounding skin. 
Oestrogen causes the lining of the vagina to mature and to contain glycogen, a 
substrate on which Candida albicans thrives. Lack of oestrogen in younger and older 
women makes vulvovaginal candidiasis much less common. 
Overgrowth of Candida albicans occurs most commonly with: 
 Pregnancy 
 Higher dose combined oral contraceptive pill and oestrogen-based hormone 
replacement therapy 
 A course of broad spectrum antibiotics such as tetracycline or amoxiclav 
 Diabetes mellitus 
 Iron deficiency anaemia 
 Immunodeficiency e.g., HIV infection 
 On top of another skin condition, often psoriasis, lichen planus or lichen 
sclerosus. 
 Other illness 
 
Symptoms of vulvovaginal candidiasis, i.e., an overgrowth of Candida albicans, 
include: 
 Itching, soreness and/or burning discomfort in the vagina and vulva 
 Heavy white curd-like vaginal discharge 
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 Bright red rash affecting inner and outer parts of the vulva, sometimes spreading 
widely in the groin to include pubic areas, inguinal areas and thighs. 
These may last just a few hours or persist for days, weeks, or rarely, months. 
Vulvovaginal candidiasis may recur just before each menstrual cycle (cyclic 
vulvovaginitis). Symptoms may sometimes be aggravated by sexual intercourse 
. 
DIAGNOSIS: 
The doctor diagnoses the condition by inspecting the affected area and 
recognising typical clinical appearance. The pH of the discharge tends to be less than 4.5 
and the diagnosis is often confirmed by a vaginal swab or vaginal smear. In recurrent 
cases the swab should be repeated after treatment to see whether Candida albicans is still 
present. 
It is best to avoid treatment for four weeks prior to a swab to improve the chance 
of positive culture. Repeated self-sampling may be used if symptoms are not present at 
the time of medical examination. The doctor should provide swabs, completed laboratory 
forms, lab bags and instructions where to send or deliver the specimens. 
Swab results can be misleading because the Candida albicans can be present 
without causing symptoms, and it can only be cultured if a certain amount is present. 
Swabs from outside the vagina can be negative, even when the yeast is present inside the 
vagina and there is a typical rash on the vulva. This is because the vaginal discharge has 
caused an irritant dermatitis, rather than the rash being directly due to infection.   
In other cases, a different species of yeast i.e. a non-albicans candida is found. 
This is not likely to cause significant symptoms; researchers debate whether these yeasts 
cause disease or not. Antifungal agents may not clear non-albicans candida from the 
vagina but it tends to disappear in time by itself. 
 
TREATMENT: 
There are a variety of effective treatments for candidiasis. Topical 
antifungal pessaries or vaginal tablets containing clotrimazole or miconazole are usually 
recommended  in mild cases a single treatment is all that is necessary. A cream 
formulation may be preferred. Oral antifungal medicines  containing   fluconazole 
or     itraconazole  may be used if Candida  albicans infection is severe or recurrent. 
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The creams can be used safely in pregnancy, but the tablets are best avoided. 
Not all genital complaints are due to candida, so if treatment is unsuccessful it 
may because of another reason for the symptoms 
RECURRENT CANDIDIASIS:[12] 
Occasionally Candida albicans infection persists despite adequate conventional 
therapy. In some women this may be a sign of iron deficiency, diabetes mellitus or an 
immune problem, and appropriate tests should be done. 
It is now thought that women who experience recurrent vulvovaginal Candida 
albicans do so because of persistent infection, rather than re-infection. The aim of 
treatment in this situation is therefore to avoid the overgrowth of candida that leads to 
symptoms, rather than necessarily being able to achieve complete eradication or cure. 
 
There is some evidence that the following measures can be helpful: 
 Cotton or moisture-wicking underwear and loose fitting clothing  avoid occlusive 
nylon pantyhose. 
 Soaking in a salt bath. Avoid soap  use a non-soap cleanser or aqueous cream 
for washing. 
 Apply hydrocortisone cream intermittently, to reduce itching and treat 
secondary dermatitis affecting the vulva. 
 Treat with an antifungal cream before each menstrual period and before antibiotic 
therapy to prevent relapse. 
 A prolonged course of a topical antifungal agent is occasionally warranted (but 
these may themselves cause dermatitis or result in proliferation of non-albicans 
candida). 
 Oral antifungal medication (itraconazole or fluconazole) may be taken regularly 
and intermittently (e.g. once a month). The dose and frequency is quite variable, 
depending on the severity of symptoms. Oral antifungal agents may be unsuitable 
in pregnancy. They may require a prescription. In New Zealand, single dose 
fluclonazole is available over the counter at pharmacies. 
 Boric acid (boron) 600mg as a suppository at night may help to acidify the vagina 
and reduce the presence of yeasts (albicans and non-albicans candida). 
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The following measures have not been shown to help: 
 
 Treatment of sexual partner  males may get a brief skin reaction on the penis, 
which clears quickly with antifungal creams. Treating the male doesn't reduce the 
number of episodes of candidiasis in their female partner. 
 Special low-sugar, low-yeast or high-yogurt diets 
 Putting yogurt in the vagina 
 Natural remedies (with the exception of boric acid). 
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MATERIALS AND METHODS 
 
           Safety and Clinical evaluation of siddha drug   
 
Study Design 
Study type: An Open Clinical trial 
Study Place: 
             Ayothidass Pandithar Hospital (OPD),  
             National Institute of Siddha, 
             Tambaram sanatorium, 
             Chennai-47. 
 
Study Period     :  12 months  
Sample size     :  40 patients 
 
Treatment 
Drug     :  PADIGARA PARPAM (Internal) [2]                                                               
Dosage      :  1 kundri(130 mg) bid, after food. 
Vehicle     :  Ghee 
Duration of drug administration :  24 days. 
 
Standard Operating Procedure 
Source of raw drug: 
                                 The required raw drug Padigaram was purchased from a well reputed 
indigenous drug shop.The raw drug was authenticated by the pharmacognosist in 
SCRI at Arumbakkam, Chennai. The raw drug will be purified and the medicine 
was prepared as per SOP in Gunapadam Laboratory of National Institute of Siddha.  
Purification of raw drug:[2] 
          The following drug was purified as per the Siddha text GUNAPADAM 
THATHU-JEEVA VAGUPU, by  Dr.Thiyagarajan, 5th edition,2009,pg-397. 
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PADIGARAM:(POTASH ALUM) 
                      Padigaram was dissolved in RO water, filtered &boiled to a semisolid form 
and then cooled. 
 
Method of Preparation PADIGARA PARPAM : 
Ingredients: 
  Purified Padigaram(POTASH ALUM) - 1 palam(35gms) 
    - 1 palam(35gms) 
    - q.s  
 
Methodology:[2] 
        
and was covered with a suitable mud plate, clay pasted cloth was applied to the 
junction of mudpot and plate & it was dried. Then it was subjected to calcination 
process  with 10-15 cow dung cakes. 
 Then the finished product was allowed to cool for sometime and finally it was 
powdered. 
Drug Storage: 
  The prepared drug will be stored in a clean and dry air tight glass container. 
Dispensing:                                                                                                                  
 The parpam (130 mg) was given to the patient in a butter paper pack. 
Subject selection:  
              Patients reporting at OPD of Maruthuvam with the symptoms of inclusion 
criteria will be subjected to screening test and documented using screening proforma. 
 
Inclusion criteria: 
 Age:21-45 yrs, married female                                                                                   
 Patient having the symptoms of profuse,thin,frothy whitish/Slightly greenish  
Discharge  or curdy discharge per vagina                                                                                                        
 Pruritis vulva, inflammation of the vulva, dysuria, lower abdominal pain,  
 low backache, dyspaerunia                                                                                                  
Patient willing to cooperate for vaginal swab examination 
 Patient willing to undergo routine blood investigation                    
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 Positive -Wet test for Trichomonas vaginalis/KOH for fungus                                 
 Patient  willing to participate in trial and signing in consent form         
 
Exclusion Criteria: 
 H/O Diabetes mellitus 
 H/O Bacterialvaginosis 
 H/O Sexually transmitted disease (syphilis, HIV, gonorrhoea) 
 H/O Non specific leucorrhea 
 Pregnancy and lactation 
 H/OMalignancy 
 
Withdrawal Criteria: 
 Intolerance to the drug and development of adverse reactions during the drug trial. 
 Poor patient compliance & defaulters. 
 Patients turned unwilling to continue in the course of clinical trial. 
 Patient  who will not take medication regularly. 
 
TEST AND ASSESSMENTS: 
A. Clinical assessment 
B. Siddha assessment 
C. Investigations 
 
Clinical Assessment:[4] 
 Profuse, thin, creamy whitish/greenish frothy or curdy discharge , 
 Pruritis vulva, 
 Inflammation of the vulva 
 Dysuria 
 Lower abdominal pain, 
 Low backache 
 Dyspareunia 
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Siddha Assessment: 
 Naadi (pulse perception) 
 Sparisam(palpable perception) 
 Naa(Tongue) 
 Niram(complexion) 
 Mozhi(voice) 
 Vizhi(eyes) 
 Malam(bowel habits) 
 Moothiram(urine) 
 Neerkuri 
 Neikuri 
 
Routine Tests and Investigations 
Blood:  
 Hb  (gms/dl)          
 Total RBC (million/cu.mm) 
 Total WBC (cubic mm) 
 Differential count :(%) 
 Polymorphs  
 Lymphocytes   
 Monocytes      
 Esinophils       
 Basophils 
 ESR(mm/hr) 
 Blood sugar level  - Fasting (mg/dl) 
                                Post prandial (mg/dl) 
                                      Random (mg/dl) 
 Lipid profile       -  Total cholesterol (mg/dl) 
o HDL(mg/dl) 
o LDL (mg/dl) 
o VLDL (mg/dl) 
o TGL (mg/dl) 
  Renal function test    -     Blood Urea (mg/dl) 
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                                           Serum Creatinine (mg/dl) 
                                           Uric acid (mg/dl) 
 
 Liver function test                   
 Serum total bilirubin (mg/dl) 
 Direct bilirubin (mg/dl) 
 Indirect bilirubin (mg/dl) 
 SGOT (IU/L) 
 SGPT (IU/L) 
 Serum Alk.phosphotase (kingÅ units) 
 Serum calcium (mg/dl)                
 Serum phosphorus (mg/dl)  
 Total protein (mg/dl)  
 Serum albumin (mg/dl)  
 Serum globulin (mg/dl)  
 Serum fibrinogen (g/dl) 
 Urine:                      
o Albumin 
o Sugar (fasting and post prandial) 
o Deposits 
o Bile salts 
o Bile pigments Urobilinogen 
 Microbiology test :     VDRL                                         
 
Specific Investigations : 
VAGINAL SMEAR : 
 Wet test for- TRICHOMONAS VAGINALIS. 
 KOH for fungus 
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Data collection forms: 
Required information was collected from each patient by using the following forms  
Forms: 
FORM l :  Screening & Selection Proforma  
FORM ll :  Case Record form 
FORM lll :  Laboratory Investigation form 
FORM IV :  Drug compliance form 
FORM V :  Patient Information Sheet 
FORM VI :  Informed Consent Form 
FORM VII :  Withdrawal Form/ Adverse reaction form (Pharmacovigilance  
                                     form) 
FORM VIII :   Dietary advice Form 
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PATIENT SCREENING 
Inclusion/Exclusion 
INCLUSION CRITERIA EXCLUSION CRITERIA 
EXCLUDED FROM TRIAL 
METHODOLOGY 
       STUDY NUMBER 
     HISTORY TAKING 
LAB INVESTIGATION 
 TRIAL DRUG  
CLINICAL ASSESSMENT 
OUTCOME 
INFORM ABOUT STUDY 
AND TRIAL DRUG 
INFORMED CONSENT FORM 
ADVERSE REACTION 
ADVICED TO TAKE 
TREATMENT IN OPD 
ABNORMAL VALUES 
         REFERRED TO 
PHARMACOVIGILANCE            
DEPARTMENT,    NIS 
ADVISED TO TAKE 
TREATMENT IN OPD 
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Study Enrolment: 
              Patient reporting at the NIS, OPD with clinical features of whitsh or yellowish 
discharge per vagina, Pruritis vulva, vulval irritation, dysuria, abdominal pain, low 
backache are chosen for enrolment based on the inclusion criteria. The patients who are 
enrolled are informed about the study trial drug, possible outcomes and the objectives of 
the study in their own language and terms understandable to them and the informed 
consent would be obtained from them in the consent form. 
 
Conduct of the Study 
               The day before starting trial drug  purgation will be 
given with in ginger juice at morning empty stomach.The 
next day rest, third day onwards the trail drug PADIGARA PARPAM -130mg twice a 
day with ghee after food will be given continously for 24 days  by the investigator in the 
OP department of Maruthuvam, NIS,  Chennai. The patients was asked to have a regular 
treatment in the OP department once in 6 days. In every visit the clinical assessment was 
recorded in the prescribed Proforma (form no:II A). The laboratory investigation was 
done before and after treatment and recorded in the prescribed format (form no: III).For 
IP patients the drug had been provided & prognosis is noted daily. Routine laboratory 
investigations & vaginal smear was done on 0th day& 24th day.   
                At the end of the trial the patients were advised to come for follow up for 2 
months for observation.  
 
Data Management: 
 After enrolling the patient in the study, a separate file for each patient was opened 
and all forms were filed in the file. Study No. and Patient No. were entered on the 
top of file for easy identification.  Whenever the study patient visits OPD during 
was made at the assessment form or other suitable forms. 
 The screening forms were filed separately. 
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 The Data recordings were monitored for completion by Guide (HOD, Dept. of 
Maruthuvam), SRO (Statistics) and the adverse event was monitored by the 
members of the Pharmacovigilance department of NIS. All forms were further 
scrutinized in presence of Investigator by Sr.Research Officer (Statistics) for 
logical errors and incompleteness of data to avoid any bias. No modification in the 
results was permitted for unbiased reports. 
      
 OUTCOME 
o PRIMARY OUTCOME: 
 It was assessed by the vaginal smear when wet test /KOH becomes 
negative for Trichomonas vaginalis/fungus after treatment & 
reduction of clinical symptoms. 
o SECONDARY OUTCOME: 
 Socio economic status , Age related to the disease will be assessed. 
 
Adverse effect and Serious effect Management: 
             If the trial patient develops any adverse reactions the patient was referred to the 
Pharmacovigilance department of NIS and documented. For any adverse effect the 
investigator will give the proper management in the OPD.  
 
Ethical issues:  
1. Informed consent was obtained from the patients after explaining about the clinical 
trial in an understandable language. 
2. After the consent of the patient (through consent form) they were enrolled in the 
study. 
3. Treatment was provided free of cost 
4. No other medicines was used except the trial drug 
5. Vaginal smear was performed in NIS clinical laboratory. 
6. To prevent any infection, while collecting blood sample from the patient, only 
Disposable syringes, disposable gloves, with proper sterilization of lab 
equipments were used. 
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      7. The data collected from the patient were kept confidentially. The patients were 
informed about the   diagnosis, treatment and follow up. 
     8. The patients who were excluded (as per the exclusion criteria)  given proper 
treatment with full care at OPD. 
     9. In conditions of treatment failure, adverse reactions patients were given alternative 
treatment at the OPD with full care through the end.        
 
 STATISTICAL ANALYSIS: 
                      All data were entered into computer using MS Access software with macro 
for logical errors and manually cross checked for data entry error. Then the data were 
and Mantel-Haenszel chi-square test was performed for determining the significance of a 
particular effect variable.   
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PREPARATION OF  PADIGARA PARPAM 
 
Ingredients:[2] 
         Padigaram (POTASH ALUM)- 1 palam(35gms) 
         - 1 palam(35gms) 
         - q.s  
 
Source of raw drug: 
                               The required raw drug Padigaram was purchased from a well reputed 
indigenous drug shop. The raw drug was authenticated by the pharmacognosist 
SCRI in arumbakkam, Chennai. The raw drug was  purified and the medicine was 
prepared as per SOP in Gunapadam Laboratory of National Institute of Siddha.  
 
Purification of raw drug:[2] 
The following drug was purified as per the Siddha text GUNAPADAM 
THATHU-JEEVA VAGUPU, by  Dr.Thiyagarajan, 5th edition,2009,pg-397. 
 
PADIGARAM:(POTASH ALUM) 
It was dissolved in RO water, filtered & boiled to a semisolid form and then 
cooled. 
 
Methodology: 
 
covered with a suitable mud plate, clay pasted cloth was applied to the junction & 
it was dried.  
 Then it was subjected to calcination  process  with 10-15 cow dung cakes. 
 Then the finished product was allowed to cool for some time and finally it was    
powdered. 
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Drug Storage: 
                    The prepared drug was stored in a clean and dry air tight glass container. 
  Dispensing:                                                                                                                            
     The parpam (130 mg) was  given to the patient in butter paper pack. 
 Dosage: 
           1 kundri(130 mg) bid, after food. 
 Vehicle:  
               Ghee 
 Duration of drug administration:  
24 days. 
 Indications: 
                      Utsoodu,vettai,neer erichal,ulluruppu ranam,baedhi,irumal. 
  Pathiyam: 
 Ichcha pathiyam  
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DRUG REVIEW 
 
ÀÊ¸¡Ãõ:[3] 
 
§ÅÚ ¦ÀÂ÷ :  
º£É¡ì¸¡Ãõ,  
ÀÊ¸¢,  
º£Éõ. 
 
¦ºö¨¸: 
ÐÅ÷ôÀ¢, 
ÌÕ¾¢ô¦ÀÕì¸¼ì¸¢, 
«Ø¸Ä¸üÈ¢, 
Òñ½¡ì¸¢, 
­º¢Å¸üÈ¢ Ó¾Ä¢ÂÉ ¬Ìõ. 
­Ð ÁÄò¨¾ì ¸ðÎõ. 
 
¦À¡Ð Ì½õ:[3] 
"º£É¦ÁÛí ¸¡ÃÁÐ º£È¢ÅÕ ÀøÄÃ¨½ 
¬¨Éì¸¡ø ¸ñ§½¡ö «É¢Ä¦Á¡Î-Á¡¿¢Äò¾¢ø 
ÐýÁ¡í ¸¢ºõÅ¡Ô §¾¡Ä¡¾ ¯ûªÆ¨Ä 
ÌýÁÁ¢¨Å §À¡ìÌ¦ÁÉì ÜÚ" 
(¦À¡-û) ÀÊ¸¡Ãò¾¢É¡ø ÀøÄÃ¨½, Â¡¨Éì¸¡ø, ¸ñ§½¡ö, §¿ò¾¢ÃÅ¡Ô, 
Ð÷Á¡Á¢º Åª÷îº¢, Å¡Ô, ¯ð ÝÎ, ÌýÁõ Ó¾Ä¢Âý ¿£íÌõ. 
 
ÁüÚõ ­Ð ­Ãò¾ À¢ò¾§¿¡ö, ­Ãò¾ô¦ÀÕìÌ, «¾¢º¡Ãõ, ÌÆó¨¾¸ÙìÌ 
¸¡Ïõ Å¡ó¾¢, §À¾¢, ¸ì¸¢ÕÁø, ¸ÀõÅ¢Ø¾ø, ¦¾¡ñ¨¼ôÒñ, ®ÚÅ¢Ã½õ, 
¦Åû¨ª, ¦ÀÕõÀ¡Î Ó¾Ä¢Â §¿¡ö¸¨ªÔõ §À¡ìÌõ. 
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ÀÊ¸¢ ­ÃñÎ ÌýÈ¢¨Â(260 Á¢.¸¢) ¬¼¡§¾¡¨¼î º¡üÈ¢ø ¿¡û ´ýÚìÌ 
ÓõÓ¨È Å£¾õ ¦¸¡ÎòÐÅÃ, ¦Àñ¸ÙìÌì¸¡Ïõ ¦Åû¨ªÔõ «¾Û¼ýÀÎ¸¢ýÈ 
¯¾¢ÃÓõ ¿¢üÌõ. 
 
PROPERTIES OF PADIGARAM 
Chemical formula  KAl(SO4)2·12H2O 
Molar mass  474.3884 g/mol 
Appearance white small crystals 
Odor watery metallic 
Density 1.725 g/cm3 
Melting point 
92 to 95 °C (198 to 203 °F; 365 to 
368 K) 
Boiling point 200 °C (392 °F; 473 K) 
Solubility in 
water 
14.00 g/100 mL (20 °C) 
36.80 g/100 mL (50 °C) 
Solubility insoluble in acetone 
Refractive index 
(nD) 
1.4564 
 
¦Åñ¦½ö ¦À¡ÐÌ½õ[3] 
"¦Åñ¦½¨Â ÔñÊ¼ Å¢óÐ¨Åô ¦ÀÕì¸¢§Áü 
Èñ¦½É ¦ÁöÅÄ¢ ¾ÉìÌÃ Á¡Ì§Á" 
 (¦À¡-¨Ã) ¦Åñ¦½¨Â ¯ñ¼¡ø ¾¡ÐÅ¢÷ò¾¢¨ÂÔõ, §¾¸ò¾¢üÌ 
Ìª¢÷îº¢¨ÂÔõ, ÀÄò¨¾Ôõ ¯ñÎÀñÏõ. 
 
ÀÍ ¦Åñ¦½öì Ì½õ:[3] 
"¸ñ½¢ ¦ÄØ§¿¡Ôí ¸ñ¦½Ã¢×õ À£¨ªÔõ§À¡ 
¦ÁñÏõ Àº¢Ô ¦ÁØõÒí¸¡ñ-¿ñ½Ã¢Â 
¬Å¢ÉÚõ ¦Åñ¦½öì ¸¸ÖõÅý §Á¸¦ÁøÄ¡õ 
âÅ¢É÷ì ¦¸øÄ¡õ Ò¸ø" 
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(¦À¡-¨Ã) ÀÍÅ¢ý ¦Åñ¨½Â¡ø ¸ñ§½¡ö, ¸ñ¦½Ã¢îºø, À£¨ª º¡Ãø, 
À¢Ã§Á¸õ ­¨Å §À¡õ. Àº¢Ôñ¼¡õ. 
 
Nutritional value of butter [15] 
 Chemically butter fat consists essentially of a mixture of triglycerides, particularly those 
derived from fatty acids, such as palmitic, oleic, myristic, and stearic acids.  
 Butter contains vitamins and minerals which include vitamin A, D, E, and K, as 
well as essential minerals like manganese, chromium, iodine, zinc, copper and 
selenium.  
 
Butter as the following actions: 
1.POWERFUL ANTIOXIDANT: 
 Natural butter contains high levels of carotene,an unusual and 
essential nutrient for human beings.  
 Carotene acts as an antioxidant,anti-infectious that boost our immune 
system. 
 
2. ANTI-CANCER PROPERTIES: 
 High levels of vitamin A and beta carotene lowers the chances of 
colorectal and prostate cancer. 
 Conjugated Linoleic acid (CLA) has also been found in significant 
levels in butter and has been connected in studies as a cancer 
prevention method. 
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¬Å¢ÉÐ À¡Ä¢ý ¦À¡Ðì Ì½õ[3] 
"À¡Ä÷ ¸¢ÆÅ÷ ÀÆïÍÃò§¾¡÷ Òñ½¡ª¢ 
Ý¨ÄÂ÷ §Á¸ò§¾¡÷ Ð÷ÀÄò§¾¡÷ ²ÖÁ¢Å÷ 
±øÄ¡÷ìÌ Á¡Ìõ ­¨ªò¾Å÷ìÌï º¡¾¸Á¡ö 
¿øÄ¡ö ÀÍÅ¢ýÀ¡ø ¿¡ðÎ" 
(¦À¡-¨Ã) ÀÍÅ¢ý À¡Ä¡ÉÐ, ÌÆó¨¾¸ðÌõ, ¸¢ÆÅ÷¸ðÌõ, À¨Æ ÍÃõ, Òñ, 
Í¨Ä, À¢Ã§Á¸õ, Ð÷ôÀÄõ, ¦ÁÄ¢× ¬¸¢Â ­¨Å¸¨ª ¯¨¼ÂÅ÷¸ÙìÌõ ¬Ìõ 
±ý¸. 
 
Cow milk: [16] 
 Milk provides essential nutrients and is an important source of dietary energy, 
high-quality proteins and fats. 
 Milk can make a significant contribution to the required nutrient intakes for 
calcium, magnesium, selenium, riboflavin, vitamin B12 and pantothenic acid. 
 Fat constitutes approximately 3 to 4 percent of the solid content of cow milk, 
protein about 3.5 percent and lactose 5 percent, but the gross chemical 
composition of cow milk varies depending on the breed.  
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PADIGARAM (Potash alum)   PURIFIED PADIGARAM 
 
 
 
 
PADIGARAPARPAM 
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BIO CHEMICAL ANALYSIS OF PADIGARA PARPAM 
 
The biochemical analysis of Padigara parpam was done in Bio chemistry lab, 
National Institute of Siddha.  
S.No EXPERIMENT OBSERVATION INFERENCE 
1.  Appearance of the sample White  in colour  
2. Test for Slicate 
a. A 500mg of the sample was 
shaken well with distilled 
water. 
b. A 500 mg of the sample was 
shaken well with 
conc.Hcl/con.H2SO4 
 
Sparingly soluble 
 
 
Presence of Silicate 
 
3. Action of Heat: 
A small amount of the sample was 
taken in a dry test tube and heated 
gently at first and then strong. 
 
No White fumes  
evolved. 
No brown fumes. 
 
 
Absence of 
Carbonate 
 Absence  of Nitrate. 
 
4. Flame Test: 
A small amount of the sample was 
made into a paste with con. HCl in a 
watch glass and introduced into non-
luminous part of the bunsen flame. 
 
No bluish green 
flame appeared 
 
Absence  of copper 
 
5. Ash Test:  
A filter paper was soaked into a 
mixture of sample and cobalt nitrate 
solution and introduced into the 
bunsen flame and ignited. 
 
No yellow colour 
flame appeared 
 
 
 
 
Absence of sodium 
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Preparation of Extract: 
5gm of Padigara parpam was weighted accurately and placed in a 250ml clean 
beaker and added with 50ml of distilled water. Then it was boiled well for about 10 
minutes. Then it was cooled and filtered in a 100ml volumetric flask and made up to 
100ml with distilled water. This preparation was used for the qualitative analysis of 
acidic/basic radicals and biochemical constituents in it. 
S.No EXPERIMENT 
OBSERVATI
ON 
INFERENCE 
 I. Test For Acid Radicals   
1. Test For Sulphate: 
a.2ml of the above prepared extract was taken 
in a test tube to this 2ml of 4%dil. ammonium 
oxalate solution was added. 
 
b.2ml of the above prepared extract was 
added with 2ml of dil.Hcl until the 
effervescence ceases off. 
Then 2ml of  Barium chloride solution was 
added. 
Cloudy 
appearance 
present 
 
A white 
precipitate 
insoluble in 
con.Hcl was 
obtained 
Absence of Sulphate 
 
 
Sulphate was not 
confirmed 
 
 
2. 
 
Test For Chloride: 
2ml of the above prepared extracts was added 
with 2ml of dil.HCl was added until the 
effervescence ceases off. Then 2ml of silver 
nitrate solution was added  
Cloudy 
appearance 
present. 
 
Presence of Chloride  
3. Test For Phosphate: 
2ml of the extract was treated with 2ml of 
dil.ammonium molybdate solution and 2ml of 
con.HN03 
No Cloudy 
yellow 
appearance  
 
Absence of Phosphate  
4.  Test For Carbonate: 
2ml of the extract was treated with 2ml dil. 
magnesium sulphate solution 
No Cloudy 
appearance 
present 
 
Absence of  carbonate 
 61 
 
5. Test For Nitrate: 
1gm of the extract was heated with copper 
turnings and concentrated H2SO4 and viewed 
the test tube vertically down. 
 No 
characteristic 
changes 
 
Absence of nitrate 
 
6. Test For Sulphide: 
1gm of the extract was treated with 2ml of 
con. HCL 
 No rotten egg 
smelling gas 
was evolved 
Absence of sulphide 
7. Test For Fluoride & Oxalate: 
2ml of extract was added with 2ml of dil. 
Acetic acid and 2ml dil.calcium chloride 
solution and heated. 
  
No cloudy 
appearance. 
 
Absence of fluoride 
and oxalate 
8. Test For Nitrite: 
3drops of the extract was placed on a filter 
paper, on that 2 drops of dil.acetic acid and 2 
drops of dil.benzidine solution were placed. 
No 
characteristic 
changes 
 
Absence of nitrite 
 
9. Test For Borate: 
50mg of the extract was made into paste by 
using dil.sulphuric acid and alcohol (95%) 
and introduced into the blue flame. 
No bluish 
green colour 
flame 
appeared 
 
Absence of borate 
 
 
II. Test For Basic Radicals 
1. Test For Lead: 
2ml of the extract was added with 2ml of 
dil.potassium iodine solution. 
No Yellow 
precipitate 
was obtained. 
 
Absence of lead 
 
2. Test For Copper: 
a. 50mg of extract was made into paste 
with con. HCl in a watch glass and 
introduced into the non-luminous part 
of the flame. 
b. 2ml of extract was added with excess 
of ammonia solution 
 
No blue 
colour 
precipitate  
No blue 
colour 
precipitate  
   
Absence of    copper 
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3. Test For Aluminium: 
To the 2ml of extract dil.sodium hydroxide 
was added in 5 drops to excess. 
 No 
characteristic 
changes  
Absence of    
Aluminium 
 
4. Test For Iron: 
a. 2ml of extract was added with 2ml of 
dil.ammonium thiocyanate solution. 
b. To the 2ml of extract added 2ml of 
ammonium thiocyanate solution and 2ml of 
con.HNO3 was added. 
No red colour 
appeared 
No blood red 
colour 
appeared 
 
Absence of Iron 
 
Absence of Iron 
 
5. Test For Zinc:  
To 2ml of the extract dil.sodium hydroxide 
solution was added in 5drops to excess and 
dil.ammonium chloride was added.  
NoWhite 
precipitate 
was formed 
 
 Absence of Zinc 
 
6. Test For Calcium:  
2ml of the extract was added with 2ml of 4% 
dil.ammonium oxalate solution. 
 Cloudy 
appearance 
and white 
precipitate 
was formed 
Presence of calcium 
 
 
7. Test For Magnesium:  
To 2ml of extract dil.sodium hydroxide 
solution was added in 5 drops to excess. 
No  White 
precipitate 
was obtained 
 
Absence of magnesium 
 
8. Test For Ammonium: 
To 2ml of extract 1 ml of Nessler's reagent 
and excess of dil.sodium hydroxide solution 
were added. 
 No Brown   
colour 
appeared 
 
Absence of ammonium 
 
9. Test For Potassium: 
25mg of extract was treated  with 2ml of 
dil.sodium nitrite solution and then treated 
with 2ml of dil.cobalt nitrate in 30% 
dil.glacial acetic acid. 
   
No Yellow 
precipitate 
was obtained 
 
 
 
Absence of potassium 
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10. Test For Sodium: 
 50mg of the extract was made into paste by 
using HCl and introduced into the blue flame 
of bunsen burner. 
No yellow 
colour flame 
evolved. 
 
 
 
Absence of sodium 
 
11. Test For Mercury:  
2ml of the extract was treated with 2ml of 
dil.sodium hydroxide solution.  
 No Yellow 
precipitate 
was obtained   
 
Absence of Mercury 
 
12. Test For Arsenic:  
2ml of the extract was treated with 2ml of 
dil.sodium hydroxide solution. 
No  Brownish 
red precipitate 
was obtained 
  
Absence of arsenic. 
 
III. Miscellaneous 
1.
  
Test For Starch: 
2ml of extract was treated with weak dil.Iodine 
solution  
 
No Blue colour 
developed 
 
Absence of 
starch 
2.
  
Test For Reducing Sugar: 
    5ml of Benedict's qualitative solution was taken 
in a test tube and allowed to boil for 2 minutes 
and add 8 to 10 drops of the extract then again 
boil it for 2 minutes. The colour changes were 
noted. 
  
No Brick red colour 
was developed  
 
Absence of  
reducing sugar 
  
3. Test For The Alkaloids: 
a) 2ml of the extract was treated with 2ml of 
dil.potassium Iodide solution. 
b)  2ml of the extract was treated with 2ml of 
dil.picric acid. 
c)  2ml of the extract was treated with 2ml of 
dil.phospho tungstic acid. 
 
 
 No Yellow colour  
 
 
Absence 
of Alkaloid 
  
4.
  
Test For Tannic Acid:  
2ml of extract was treated with 2ml of dil.ferric 
chloride solution  
  
No black precipitate 
was obtained  
 
Absence of 
Tannic acid 
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5.
  
Test For Unsaturated Compound: 
To the 2ml of extract 2ml of dil.Potassium 
permanganate solution was added.  
 Potassium 
permanganate was 
not decolourised 
  Absence of 
unsaturated 
compound 
6.
  
Test For Amino Acid: 
2 drops of the extract was placed on a filter paper 
and dried well. 20ml of Burette reagent was 
added. 
 
No violet colour 
 
 
Absence of 
amino acid 
 
 
 
  
 RESULTS: 
  Silicate, Chloride, Calcium are present in padigara parpam. 
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ICP-OES AND SEM REPORTS OF PADIGARA PARPAM 
Padigara Parpam    
(wt:0.20155g) 
Al 396.152                  4.025 mg/L 
As 188.979 BDL 
Ca 315.807 02.360 mg/L 
Cd 228.802  BDL 
Cu 327.393 BDL 
Hg 253.652 BDL 
K 766.491  123.821 mg/L 
Mg 285.213  01.304 mg/L 
Na 589.592  04.310 mg/L 
Ni 231.604  BDL 
Pb 220.353  BDL 
P 213.617  16.341 mg/L 
S 180.731  21.324 mg/L 
 
ICP-OES 
Emission spectrometry is based on the principle that atoms or ions in an excited 
state tend,to revert back to the ground state and in so doing emit characteristic wavelength 
and intensity of that light is proportional to the concentration of that particular element in 
the sample solution 
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Sample Required  
 
     Sample required is about 10-20mg for solids and approximately 25ml for  
liquids.Samples should be non-explosive and non-corrosive. 
Application 
 
     This technique is used for quantitative and qualitative determination of the metals and 
metalloids in the following sample. 
Biological Geological 
Enviromental Pharmaceutical 
Industrial Aqueous and Organic  
 
F E I Quanta FEG 200 - High Resolution Scanning Electron Microscope  
 
                 The Quanta 200 FEG scanning electron microscope (SEM) is a versatile high 
resolution scanning electron microscope with three modes of operation, namely, the high 
vacuum (HV) mode for metallic (electrically conducting) sample, low vacuum (LV) and 
environment scanning electron microscope (ESEM) modes for insulating, ceramic, 
polymeric (electrically insulating) and biological samples respectively. Apart from giving 
the high resolution surface morphological images, the Quanta 200 FEG also has the 
analytical capabilities such as detecting the presence of elements down to boron (B) on 
any solid conducting materials through the energy dispersive X-ray spectrometry (EDX) 
providing crystalline information from the few nano meter depth of the material surface 
via electron back scattered detection (BSD) system attached with microscope and 
advanced technological PBS (WDS) for elemental analysis. 
 
Resolution: 1.2 nm gold particle separation on a carbon substrate 
Magnification: From a min of 12x to greater than 1, 00,000 X 
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 APPLICATION INCLUDE  
Materials evaluation 
 Grain size 
 Particle size 
distributions 
 Material 
homogeneity 
 Inter metallic 
distribution 
Failure analysis 
 Contamination location 
 Mechanical damage 
assessment 
 Micro-crack location 
  
Quality Control 
screening 
 
 
 comparison 
 Dimension 
verification 
 Gate width 
measurement 
  
 
Sample required  
 
General Size:. Any dimension (Height or Diameter): Less than 10 mm. The ideal 
shape of a sample is that of a button on your shirt. However, other sizes can also be 
accommodated only after a discussion with the system operator. 
Conductivity (Electrical):Conducting or at least semiconducting. If sample is not 
electrically conducting, it will require silver or gold coating. If the sample is a powder, 
make a normal button size pellet of the powder. If the sample is insulator or polymeric or 
electrically non-conducting it needs to be coated with carbon. 
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Results and Interpretation of SEM analysis: 
        The morphology of the Padigara parapam drug can be determined by SEM (FEI 
Quanta). A representative portion of each sample must be  sprinkled onto a double side 
carbon tape and mounted on aluminium stubs, in order to get a higher quality secondary 
electron image for SEM examination. We have observed from SEM photographs that 
particles are spherical in shapes and sizes are in the range from 0.5 micron  to 4 microns. 
Although the particle sizes of different batches showed similarity, it seems that these 
particles are aggregates of much smaller particles. When dispersed in an aqueous 
medium, these preparations form a negatively charged hydrophobic particle suspension. 
This hydrophobicity gives these particles a tendency to aggregate together to form larger 
particles. This parpam exhibited larger sizes and agglomeration of the particles. 
Therefore, the comparatively larger size may be due to the agglomeration of the particles 
by repeated cycles of calcinations involved in preparation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 69 
 
ACUTE ORAL TOXICITY  OECD GUIDELINES  423 
 
Acute toxicity study was carried out as per OECD guideline (Organization for 
Economic Co - operation and Development, Guideline-423 
 
Animal : Healthy Wistar albino female rat weighing 180 220 gm 
Studied carried out at three female rat under fasting condition, signs of toxicity 
was observed for every one hour for first 24 hours and every day for about 14 days from 
the beginning of the study. 
 
INTRODUCTION:  
The acute toxic class method is a stepwise procedure with the use of 3 animals of 
a single sex per step. Depending on the mortality and/or the moribund status of the 
animals, on average 2-4 steps may be necessary to allow judgment on the acute toxicity of 
the test substance. Morbid animals or animals obviously in pain or showing signs of 
severe and enduring distress shall be humanely killed, and are considered in the 
interpretation of the test  results  in  the  same  way  as  animals  that  died  on  test.  The 
method allows for the determination of an LD50 value only when at least two doses result 
in mortality higher than 0% and lower than 100%. 
 
PRINCIPLE:  
   It is the principle of the test that based on a stepwise procedure with the use of a 
minimum  number  of  animals  per  step,  sufficient  information  is  obtained  on  the  
acute toxicity  of  the  test  substance  to  enable  its  classification.  The substance is 
administered orally to a group of experimental animals at one of the defined doses.  The 
substance is tested using a stepwise procedure, each step using three animals of a single 
sex. Absence or presence of compound-related mortality of the animals dosed at one step 
g of three additional animals at the next 
higher or the next lower dose level. The method will enable a judgment with respect to 
classifying the test substance to one of a series of toxicity classes.   
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METHODOLOGY 
 
Selection of animal species:  
   The preferred rodent species is rat, although other rodent species may be used.  
Healthy  young  adult  animals  of  commonly  used  laboratory  strain Swiss albino is 
used .  Females should be nulliparous and non-pregnant.  Each animal at the 
commencement of its dosing should be between 8 and 12 weeks old and its weight should 
fall in an interval within±20 % of the mean weight of the animals.   
 
Housing and feeding conditions:   
   The  temperature  in  the  experimental  animal  room  should  be  22ºC  (+3ºC). 
Although  the  relative  humidity  should  be  at  least  30%  and  preferably  not  exceed  
70% other than during room cleaning the aim should be 50-60%. Lighting should be 
artificial, the sequence being 12 hrs light, 12 hrs dark. For feeding, conventional 
laboratory diets may be used with an unlimited supply of drinking water. Animals may be 
grouped and tagged by dose, but the number of animals per cage must not interfere with 
clear observations of each animal.   
 
Preparation of animals:   
   The animals are randomly selected, marked to permit individual identification, 
and kept in their cages for at least 7 days prior to dosing to allow for acclimatization to 
the laboratory conditions.  
 
Observation done: 
 
Parameters Observations 
Body weight Normal 
Assessments of posture Normal 
Signs of Convulsion 
Limb paralysis 
Absence of sign (-) 
Body tone Normal 
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Lacrimation Absence 
Salivation Absence 
Change in skin color No significant colour change 
Piloerection Normal 
Defecation Normal 
Sensitivity response Normal 
Locomotion Normal 
Muscle grip ness Normal 
Rearing Mild 
Urination Normal 
 
 
1. Alertness 2.Aggressiveness 3. Pile erection 4. Grooming   5.Gripping   6. Touch 
Response  7. Decreased Motor Activity   8.Tremors 9 Convulsions 10. Muscle Spasm 11. 
Catatonia 12.Musclerelaxant 13.Hypnosis 14.Analgesia15.Lacrimation 16. Exophthalmos 
17. Diarrhea   18. Writhing   19 Respiration   20.  Mortality. 
Acute toxicity: 
In the acute toxicity study, the rats were treated with different concentration of P. 
Parpam from the range of 5mg/kg to 2000mg/kg which did not produce signs of toxicity, 
behavioral changes, and mortality in the test groups as compared to the controls when 
observed during 14 days of the acute toxicity experimental period. These results showed 
that a single oral dose of the extract showed no mortality of these rats even under higher 
dosage levels indicating the high margin of safety of this extract. In acute toxicity test 
compound P.Parpam was found to be non toxic at the dose level of 2000mg/ kg body 
weight.  
 
 
 
 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
2000 + - - - - + - - - - - + - + - - - - - - 
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Repeated dose 28-day sub-acute oral toxicity study of  
P.Parpam on rats  
(OECD  407 guidelines) 
 
Sub-acute toxicity studies were carried out according to OECD 407 and rats were 
divided into 3 groups of 10 animals (5 male and 5 female). Group I served as control 
treated with normal saline and Group-II and III were treated with P.Parpam at the dose of 
200 & 400 mg/kg/day for 28 days. The toxic symptoms such as signs of toxicity, 
mortality and body weight changes were monitored. Rats were anesthetized with ether at 
the end of the treatment period. All rats were sacrificed after the blood collection. 
                                 
Sub acute toxicity 
The dose selected for the sub acute toxicity study was 200mg, 400mg/kg. All the 
animals were free of intoxicating signs throughout the dosing period of 28 days. No 
physical changes were observed throughout the dosing period. No mortality was observed 
during the whole experiment. No significant changes were observed in the values of 
different parameters studied when compared with controls and values obtained were 
within normal biological and laboratory limits. The weights of organs recorded did not 
show any significant differences in the treatment and the control group indicating that P. 
Parpam was not toxic to kidney, liver, spleen, brain There was no significant changes 
were observed in hemoglobin (Hb), red blood cell (RBC), white blood cell (WBC), 
packed cell volume (PCV), Erythrocyte sedimentation rate (ESR) in all the treated groups 
as compared to respective control groups. 
 
Histopathology:  
Histopathological investigation of the vital organs was done. The organ pieces (3-
5µm thick) were preserved and were fixed in 10% formalin for 24 h and washed in 
running water for 24 h. Samples were dehydrated in an auto technicon and then cleared in 
benzene to remove absolute alcohol.  Embedding was done by passing the cleared 
samples through three cups containing melted paraffin at 50°C and then in a cubical block 
stained with Haematoxylin-eosin.   
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The organs included brain, heart, kidneys, liver and lungs of the animals were 
preserved they were subjected to histopathological examination. 
 
Statistical analysis:  
Findings such as clinical signs of intoxication, body weight changes, food 
consumption, and hematology and blood chemistry were subjected to one-way Anova.  
 5.0 
 
Change in body weight 
Treatment 0th day 7th day 14th day 21st day 28th day 
Control 185.13±2.44 188.50±4.28 194.83±12.46 198.84±4.34 207.46±8.41 
100mg/kg 183.86±1.32 190.33±4.60 194.33±16.08 201.83±4.61 209.46±12.45 
200mg/kg 178.83±3.50 180.66±9.74 183.50± 7.58 192.01±14.56 196.43±7.59 
 
         
     Organ Weight 
Dose 
Relative Organ Weight of rats (gm) 
Liver Kidney Brain Spleen 
Control  2.72±0.2 0.68±0.12 0.48±0.02 0.18±0.14 
100mg/kg 2.86±0.1 0.64±0.12 0.41±0.01 0.14±0.72 
200mg/kg 2.76±0.1 0.67±0.13 0.49±0.01 0.19±0.76 
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                 Kidney                      Liver   
       
 
 
 
 
 
 
 
 
  
Spleen                                            Brain 
 
 
 
 Photomicrograph of liver tissue of control rats showing normal hepatic cells with 
central vein (CV) and sinusoidal dilation (S). 
 Kidneys cells showed normal histological architecture and the presence   of small 
number of resident lymphocytes in the portal connective stroma. 
 Spleen cells showing normal histology expanded white pulp, red pulp and central 
arteriole 
 Brain -The segment of cerebellum, with the normal architecture indicating no 
structural changes 
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Haematological parameter 
 
Control 
P.Parpam 
200mg/kg 400mg/kg 
Total R.B.C. count (×106 
mm 3). 
8.83±0.08 8.60±0.11 8.56±0.18 
Total W.B.C. Count (×103 
mm 3). 
11.80±0.46 11.27±0.37 11.60±0.23 
Haemoglobin (Hb) (g/dl) 15.67±0.24 15.37±0.21 15.63±0.31 
Hematocrit (%). 41.00±0.57 39.67±0.88 38.67±0.73 
Platelets (×103 mm 3). 850.0±13.11 865.3±3.52 871.7±4.410 
Lymphocytes(%). 82.67±1.76 73.33±2.40 80.00±1.15 
Neutrophils (%). 22.00±1.15 18.73±0.93 19.93±0.24 
 
 
Biochemical Parameters  
 
Biochemical parameter 
 
Control 
P.Parpam 
200 mg/kg 400mg/kg 
Creatinine (mg/dl) 0.63± 0.07 0.68± 0.06 0.59± 0.16 
Urea (mg/dl) 15.67± 1.20 16.60± 0.87 14.87± 0.75 
Triglycerides (mg/dl) 46.33± 0.88       52.33± 1.45 48.00± 1.155 
Total Cholesterol (mg/dl) 42.00± 2.30 50.67± 2.40 49.33± 1.453 
Total protein (mg/dl) 4.00± 0.41 3.93± 0.08 4.03± 0.21 
Albumin (g/dl) 2.43± 0.32 2.573± 0.11 2.40± 0.25 
AST (IU/L) 118.3± 1.45 99.00± 1.52 108.0± 5.03 
ALT (IU/L) 64.00± 2.30 56.00± 1.08 60.00± 1.15 
ALP (IU/L) 180.7± 1.76 151.7± 3.38 157.0± 7.93 
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Kidney      Liver    Spleen 
                    
 
Brain 
 
 
 
 
 
 
 
 Normal liver cells with hepatocyte , central vein and portal triad . 
 Kidneys cells showed less number of degenerated cells  
 Spleen cells showing normal histology white pulp, red pulp and central arteriole 
 Brain cells with mild degeneration in the cortex. 
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 OBSERVATION AND RESULTS 
 
             For the clinical study 40 out patients were selected and treated in OPD No 1, 
Department of Maruthuvam, Ayothidoss pandithar Hospital, National Institute of 
Siddha,Chennai-47.  
            Results were observed with respect to the following criteria. 
                                           1. Age distribution 
                                           2. Food habits 
                                           3. Family history 
                                           4. Socio-economic status 
         5. Gunam 
         6. Paruva kalam (season) 
         7. Thinai 
                                           8. Kosangal 
                                           9. Ezhu udal thathukkal 
                                          10. Vatham                                          
                                          11. Pitham 
                                          12. Kabam 
      13. Clinical manifestations 
                                          14. Chronicity of illness 
                                          15. Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 86 
 
 
1. AGE DISTRIBUTION: 
 
Table 1: 
 
AGE No of patients Percentage 
21-30 16 40% 
31-40 19 49% 
41-45 5 11% 
 
 
 
 
 
 
INFERENCE:  
                     21-30 age group were 40% (16 cases), 31-40 age group were 49% (19 
cases), 41-45 age group were 11% (5 cases) 
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 87 
 
2. FOOD HABITS: 
 
Table 2: 
Food habits No. of patients Percentage (%) 
Vegetarian 12 30% 
Non vegetarian 28 70% 
 
 
 
 
 
 
 
INFERENCE:     
 Non vegetarian (70%) are more prone to Kirumi Yoni Rogam than vegetarian (30%). 
 
 
 
 
30%
70%
FOOD HABITS
Vegetarian Non vegetarian
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3. FAMILY HISTORY: 
 
Table 3: 
 
 Family history No family history 
No of patients 16 24 
Percentage 40% 60% 
 
 
 
 
 
INFERENCE: 
                Among 40 patients 40% of cases (16) had a family history of kirumi yoni 
rogam and 60% of cases (24)  had no family history. 
 
 
 
40%
60%
FAMILY HISTORY
Family histroy No family histroy
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3. SOCIO ECONOMIC STATUS: 
 
Table 4: 
S.no Economic status No of cases Percentage (%) 
1. Poor 21 51% 
2. Middle  11 29% 
3. Rich 8 20% 
 Total 40 100% 
 
 
 
 
 
INFERENCE:  
 
 Among 40 patients 51% of cases (21) were under poor socio-economic status, 29% of 
cases (11) were from middle class family and 20% of cases (8) were from rich. 
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5. GUNAM: 
Table 5: 
 
Gunam No of patients Percentage (%) 
Sathuva gunam 0 0% 
Rasatha gunam 40 100% 
Thamo gunam 0 0% 
 
 
 
 
INFERENCE:  
            All the 40 cases (100%) were found to posses Rasatha gunam. 
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6. PARUVA KAALAM: 
 
Table 6: 
Season No. of cases Percentage  (%) 
Kaarkaalam 
 
0 0% 
  Koothirkaalam 0 0% 
  Munpanikaalam 
 
0 0% 
  Pinpanikaalam 29 71% 
  Ilavenil kaalam 
 
11 29% 
Mudhuvenil kaalam 0 0% 
 
 
 
 
 
INFERENCE:  
 Among 40 cases, most of the cases 29 (71%) were seems to be reported in 
Pinpanikaalam and in Ilavenil kaalam it was 11 (29%). 
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7.THINAI: 
 
Table 7: 
 
Thinai No. of patients Percentage(%) 
Kurinji 0 0% 
Mullai 0 0% 
Marutham 18 45% 
Neithal 22 55% 
Paalai 0 0% 
 
 
 
 
 
INFERENCE:  
 45%  of cases (18) were from Marutha nilam, 55% of cases (22) were from 
Neithal nilam. 
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8. KOSANGAL: 
 
Table8: 
Kosam No. of cases Percentage (%) 
Annamaya kosam 26 65% 
Pranamaya kosam 0 0% 
Manomaya kosam 0 0% 
Vignanamaya kosam 8 20% 
Aanandhamaya kosam 40 100% 
 
 
 
 
INFERENCE:  
  
 Annamayakosam was affected in 65% of cases (26), Vignanamaya kosam was 
affected in 20% of cases (8), Aanandhamaya kosam was affected in 100% of cases (40). 
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9. EZHU UDAL THATHUKKAL: 
 
Table 9: 
Udal thathukkal No. of cases Percentage (%) 
Saram 26 65% 
Seneer 5 11% 
Oon 0 0% 
Kozhuppu 0 0% 
Enbu 7 19% 
Moolai 7 19% 
Suronitham 100 100% 
 
 
 
INFERENCE:  
           
   In ezhu udal thathukkal Saaram (general tiredness, loss of appetite) was affected 
in 26 cases (65%), Seneer (low hemoglobin level) was affected in 5 cases (11%)  , Enbu 
and Moolai was affected in 7 cases (19%), Suronitham (vaginal discharge) was affected 
in all cases (100%). 
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10. VAATHAM: 
 
Table 10: 
Vaatham No. of cases Percentage (%) 
Praanan 0 0% 
Abaanan 40 100% 
Udhaanan 0 0% 
Viyaanan 23 59% 
Samaanan 40 100% 
Naagan 0 0% 
Koorman 0 0% 
Kirukaran 26 65% 
Devathaththan 32 80% 
Thananjeyan 0 0% 
 
 
 
INFERENCE:  
 Abaanan (vaginal discharge, dysuria, lower abdominal pain) was affected in all  
cases (100%), Viyaanan (pain in the low back and both the knees) was affected in 23 
cases (59%) ,  Samaanan (vaginal discharge, dysuria, lower abdominal pain, general 
tiredness) was affected in all cases (100%), Kirukaran (loss of appetite) was affected in 
26 cases (65%) , Devathaththan (general tiredness ) was affected in 32 of cases (80%). 
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11.PITHAM: 
 
Table 11: 
Pitham No. of cases Percentage (%) 
Anal 26 65% 
Ranjagam 5 11% 
Pirasagam 5 11% 
Saathagam 32 80% 
Aalosagam 0 0% 
 
 
 
 
INFERENCE: 
 Among 40 patients Anal pitham (loss of appetite) was affected in 26 cases (65%), 
Ranjaga pitham and Prasagam ( low hemoglobin level, paleness) was affected in 5 
cases(11%) each, Saathagam (low back pain, general tiredness)  was affected in 32 cases 
(80%). 
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12.KABAM: 
 
Table12: 
Kabam 
 
No. of cases 
 
Percentage (%) 
Avalambagam 32 80% 
Kilethagam 26 65% 
Pothagam 0 0% 
Tharpagam 0 0% 
Santhigam 32 80% 
 
 
 
INFERENCE: 
 Among 40 patients Avalambagam (since the other types of kabam are affected) 
was affected in 32 cases (80%),Kilethagam (loss of appetite) was affected in 26 cases 
(65%), Santhigam (low back pain, knee joint pain) was affected in 32 cases (80%). 
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13. CLINICAL MANIFESTATIONS: 
Table 13: 
Clinical features No. of cases Percentage (%) 
Before 
treatment 
After 
treatment 
(Response) 
Before 
treatment 
After 
treatment 
(Response) 
Profuse, thin, creamy, 
whitish/slightly greenish 
frothy discharge  or 
curdy discharge 
40 34 100% 85% 
Pruritis vulva 32 24 80% 60% 
Inflammation of the 
Vulva 
6 6 15% 15% 
Dysuria 18 18 45% 45% 
Lower Abdominal pain 27 24 68% 60% 
Low back ache 30 16 75% 40% 
Dyspareunia 13 9 32% 21% 
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14. CHRONICITY OF ILLNESS : 
 
Table 14: 
Duration of illness No. of cases Percentage (%) 
0-6 months 13 33% 
6 months -1year 17 42% 
1-3 years 6 15% 
3-5 years 4 10% 
Total 40 100% 
 
 
 
 
INFERENCE: 
 Among 40 patients 13cases (33%)  suffered from  this disease up to 6 months, 17  
cases(42%)  suffered upto 1 year, 6 cases (15%)  suffered up to 3 years, 4 cases (10%) suffered up 
to 5 years. 
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15. RESULTS: 
 
Table 15: 
       RESULTS                       No.of cases               Percentage (%) 
Before treatment 
Positive cases 
After treatment 
Negative cases 
Before treatment 
Positive cases 
After 
treatment 
Negative 
cases 
     WET 
TEST(Trichomonas 
vaginalis) 
13 8 31% 20% 
     KOH for fungus 
(Candida albicans) 
27 18 69% 45% 
     Total 40 14 100% 32% 
 
 
INFERENCE: 
 Among 40 patients ,13 cases (31%) showed positive to wet test (Trichomonas vaginalis) 
in before treatment and 8 cases(20%) showed negative to wet test (Trichomonas vaginalis)  in 
after treatment, 27 cases (69%) showed positive to KOH for fungus (Candida albicans) in before 
treatment and 18 cases (45%) showed negative to KOH for fungus (Candida albicans)  in after 
treatment. 
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OBSERVATION OF CLINICAL LABORATORY INVESTIGATIONS 
At the time  of admission to the trial, in all the patients the following parameters observed, 
                     I.  Routine blood investigations,    
1.Haemoglobin estimation ,  
2.Total WBC count,   
3.total RBC count  
4.Differential count,   
5.Erythrocyte sedimentation Rate, 
    
        II. Blood sugar  
1.Fasting  
2.Post prandial   
        III. Liver function test,   
                     IV. Renal function test,   
                     V. Serum Lipid Profile, 
 
                     VI. Urine examination   
1.Albumin  
2.Sugar  
3.deposit   
 
                     VIII. Microbiology 
 
1.VDRL 
2.Wet test 
3.KOH for fungus 
 
 
         IX. Neer kuri, Nei kuri  also observed. 
 114 
 
 115 
 
 116 
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SATISTICAL 
ANALYSIS 
 
 
 
 
 118 
 
Statistical Analysis:   
All collected data were entered into computer using MS Excel software. The data 
entry was cross-checked manually with CRF. The data was analysed using STATA 
software. The probability value 0.05 was taken as significant level. 
employed to determine the significance of clinical symptoms, total cell count, pus cells, 
epithelial cells before and after treatment.  
  
Mean ±Standard deviation of   Clinical symptoms - Before and After treatment 
 
The clinical symptoms before treatment and after treatment were 3.225 and 1.025 
respectively and the reduction of clinical symptoms was highly significant. The  
percentage of reduction of clinical symptoms is 68.22%(1.025÷3.225×100=31.78,100-
31.78=68.22%) 
 
Mean ±Standard deviation of   Total cell count  - Before and After treatment 
 
The Total cell count  before treatment and after treatment were 7564.75 and 7830 
respectively and it was not  highly significant.  
 
 
 
 
Treatment status Mean ±Std deviation 
Significance 
 
Clinical symptoms- BT 3.225±0.181 t = 15.2656, p <0.0001 
 
Highly significant Clinical symptoms- AT 1.025±0.149 
Treatment status Mean ±Std deviation 
Significance 
 
Total cell count  - BT 7564.75±270.140 t = -1.1876, p <0.2422 
 
Not  significant Total cell count  - AT 7830±307.308 
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wet test KOH for fungus wet test KOH for fungus
1 H22960 23/F Positive Neg Neg Neg
2 H28142 45/F Positive Neg Neg Neg
3 H25871 35/F Neg Positive Neg Positive
4 H28208 29/F Neg Positive Neg Neg
5 H29028 29/F Neg Positive Neg Neg
6 H27729 38/F Neg Positive Neg Positive
7 H33752 26/F Neg Positive Neg Neg
8 H52862 37/F Positive Neg Positive Neg
9 H35141 26/F Neg Positive Neg Neg
10 H57358 33/F Neg Positive Neg Neg
11 H32430 21/F Neg Positive Neg Positive
12 H46840 31/F Neg Positive Neg Neg
13 H47479 35/F Neg Positive Neg Neg
14 H39658 39/F Neg Positive Neg Positive
15 H36165 30/F Neg Positive Neg Neg
16 H40688 37/F Positive Neg Positive Neg
17 H40766 24/F Neg Positive Neg Neg
18 H34331 42/F Positive Neg Neg Neg
19 H37543 25/F Neg Positive Neg Neg
20 H50741 27/F Positive Neg Neg Neg
21 H49447 29/F Neg Positive Neg Neg
22 H40802 40/F Positive Neg Positive Neg
23 H45393 38/F Neg Positive Neg Positive
24 H39565 19/F Neg Positive Neg Neg
25 H32020 25/F Positive Neg Neg Neg
26 H52309 40/F Positive Neg Neg Neg
27 H39708 28/F Neg Positive Neg Positive
28 H29167 28/F Neg Positive Neg Neg
29 H29128 34/F Positive Neg Neg Neg
30 H40791 34/F Neg Positive Neg Neg
31 H33952 30/F Neg Positive Neg Neg
32 H28661 45/F Positive Neg Neg Neg
33 H28607 32/F Neg Positive Neg Positive
34 H25312 36/F Neg Positive Neg Neg
35 H47489 41/F Positive Neg Positive Neg
36 H25330 32/F Neg Positive Neg Positive
37 H29971 30/F Neg Positive Neg Neg
38 H24157 20/F Positive Neg Positive Neg
39 H67913 44/F Neg Positive Neg Positive
40 H37527 31/F Neg Positive Neg Neg
BEFORE AND AFTER TREATMENT OF 1-40 PATIENTS WET TEST AND KOH FOR FUNGUS REPORTS
RESULTS : The percentage of wet test negative is 61.5% and the percentage of KOH for fungus negative is 66.6%.
S.NO OP. No Age/ sex BT-Microbiology AT-Microbiology
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Mean ±Standard deviation of  Pus cells - Before and After treatment 
 
 
 
The Pus cells before treatment and after treatment were 5.15 and 3.75 respectively 
and the reduction of pua cells  was moderately significant. 
   
 Mean ±Standard deviation of Epithelial cells - Before and After treatment 
 
 
The epithelial cells before treatment and after treatment were 5.2 and 3.95 
respectively and it was not significant. 
 
 
 
 
 
 
 
 
 
Treatment status Mean ±Std deviation 
Significance 
 
Clinical symptoms- BT 5.15±0.607 t = 2.7662, p <0.0086 
 
Moderately significant Clinical symptoms- AT 3.75±0.410 
Treatment status Mean ±Std deviation 
Significance 
 
Epi cells- BT 5.2±0.668 t = 1.1810, p <0.2447 
 
Not significant Epi cells- AT 3.95±0.751 
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DISCUSSION 
 
 Kirumi Yoni Rogam is one among the 4448 diseases. This disease is mainly due 
to aggravated pitha humour which is evident from the quote mentioned below, 
 
                  "À¸÷À¢ò¾ Å¢ó¨¾ÂÄ¡Ð §Á¸õ Å¡Ã¡Ð"[7] 
                                                                        - §¾¨ÃÂ÷ 
 
                  As per saint yougi, Kirumi Yoni Rogam is one among the 20 types of Yoni 
Rogam which can be correlated with specific leucorrhea (Trichomoniasis, Moneliasis etc) 
in Modern science. 
                Reproductive health is closely associated with culture of a country as it is well 
appreciated from the poetic version of Saint Yougi i.e., excessive lust will be the 
precipitating factor for Kirumi Yoni Rogam. 
   Kirumi Yoni Rogam is one, which affects the women commonly and frequently. 
Women in any reproductive age group and even young girls are commonly affected by 
Kirumi Yoni Rogam. The incidence of Kirumi Yoni Rogam is found in women 
irrespective of their socio-economic status. 
                   Vaginal infection is more common in women of childbearing age & in older 
women (post menopausal period).The factors like increasing age, illiteracy, low 
socioeconomic status, high parity, induced abortion & place of delivery are all 
contributing factors for occurrence of vaginal discharge. so the investigator has chosen 
the disease Kirumi yoni rogam to find out a solution and prevent the complications of it 
through siddha system of medicine.  
                  The present study is a preliminary case study of which 40 cases were selected 
according to the clinical features mentioned in the poetic version of Saint Yougi in the 
text of Magalir maruthuvam. Siddha method of diagnosis was carried out for all the 
patients and also modern investigations were done as per the protocol.   
 
 Institutional ethical committee clearance was obtained for this study.  
 As per Standard operative procedure  the drug  PADIGARA PARPAM was 
prepared at NIS,   
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 Drug  Name  :  PADIGARA PARPAM[2] 
 Dosage           :  130mg (twice a day) after food with ghee 
 Duration        :  24 Days   
 Haematological , Urine examination and microbiological studies  were done for 
the patients at NIS clinical laboratory before treatment and as well as after  
treatment.   
 The drug was subjected to the qualitative  biochemical analysis in NIS and  
quantitative Physico chemical analysis in SCRI, Arumbakkam, Chennai.  
 The physico chemical analysis of Padigara parpam shows, 
 
o Loss on drying at 105°C       =  4.39% 
o Total ash   =  77.597% 
o Water soluble ash  =  12.105% 
o Acid insoluble ash  =  36.993% 
o pH    =  3.80 
 
 The presence of following minerals have been reported by the analysis of finished 
product.  
Silicate ,Chloride and Calcium  are present in Padigara parpam.  
 The drug was subjected to quantitative  analysis and morphological study ( ICP-
OES and SEM in IIT), Chennai. Padigara parpam shows the quantitative 
measurement of the following minerals , 
  
 Al 396.152         4.025 mg/L 
 Ca 315.807 02.360 mg/L 
 K 766.491 123.821 mg/L 
 Mg 285.213 01.304 mg/L 
 Na 589.592 04.310 mg/L 
 P 213.617 16.341 mg/L 
 S 180.731 21.324 mg/L 
 
        The morphology of the Padigara parapam drug can be determined by SEM (FEI 
Quanta). A representative portion of each sample must be sprinkled onto a double side 
carbon tape and mounted on aluminium stubs, in order to get a higher quality secondary 
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electron image for SEM examination. We have observed from SEM photographs that 
particles are spherical in shapes and sizes are in the range from 0.5 micron  to 4 microns. 
Although the particle sizes of different batches showed similarity, it seems that these 
particles are aggregates of much smaller particles. When dispersed in an aqueous 
medium, these preparations form a negatively charged hydrophobic particle 
suspension. This hydrophobicity gives these particles a tendency to aggregate together to 
form larger particles. This parpam exhibited larger sizes and agglomeration of the 
particles. Therefore, the comparatively larger size may be due to the agglomeration of the 
particles by repeated cycles of calcinations involved in preparation. 
 
 The toxicological studies of Padigara parpam was done in K.K college of 
pharmacy, Gerukambakkam. 
 
Acute toxicity: 
In the acute toxicity study, the rats were treated with different concentration of P. 
Parpam from the range of 5mg/kg to 2000mg/kg which did not produce signs of toxicity, 
behavioral changes, and mortality in the test groups as compared to the controls when 
observed during 14 days of the acute toxicity experimental period. These results showed 
that a single oral dose of the extract showed no mortality of these rats even under higher 
dosage levels indicating the high margin of safety of this extract. In acute toxicity test 
compound P.Parpam was found to be non toxic at the dose level of 2000mg/ kg body 
weight.  
 
 Sub acute toxicity 
The dose selected for the sub acute toxicity study was 200mg, 400mg/kg. All the 
animals were free of intoxicating signs throughout the dosing period of 28 days. No 
physical changes were observed throughout the dosing period. No mortality was observed 
during the whole experiment. No significant changes were observed in the values of 
different parameters studied when compared with controls and values obtained were 
within normal biological and laboratory limits. The weights of organs recorded did not 
show any significant differences in the treatment and the control group indicating that P. 
Parpam was not toxic to kidney, liver, spleen, brain There was no significant changes 
were observed in hemoglobin (Hb), red blood cell (RBC), white blood cell (WBC), 
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packed cell volume (PCV), Erythrocyte sedimentation rate (ESR) in all the treated groups 
as compared to respective control groups. 
 
The histopathologial reports shows the following features, 
 Normal liver cells with hepatocyte , central vein and portal triad . 
 Kidneys cells showed less number of degenerated cells.  
 Spleen cells showing normal histology white pulp, red pulp and central arteriole. 
 Brain cells with mild degeneration in the cortex. 
 
Observation with reference to age group:  
              21-30 age group were 40% (16 cases), 31-40 age group were 49% (19 cases), 41-
45 age group were 11% (5 cases) 
 
Observation with reference to food habits:  
 Non vegetarian (70%) are more prone to Kirumi Yoni Rogam than vegetarian (30%). 
 
 Observation with reference to family history:  
              Among 40 patients 40% of cases (16) had a family history of kirumi yoni rogam 
and 60% of cases (24)  had no family history. 
 
 Observation with reference to socio-economic status :  
 Among 40 patients 51% of cases (21) were under poor socio-economic status, 29% of 
cases (11) were from middle class family and 20% of cases (8) were from rich. 
 
Observation with reference to gunam :  
All the 40 cases (100%) were found to posses Rasatha gunam. 
 
Observation with reference to paruva kaalam :  
Among 40 cases, most of the cases 29 (71%) were seen to the trial in 
Pinpanikaalam and in Ilavenil kaalam 11 (29%). 
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Observation with reference to thinai :  
45% (18) of cases were from Marutha nilam, 55% (22) of cases were from Neithal 
nilam. 
 
Observation with reference to kosangal :  
     Annamayakosam was affected in (26) 65% of cases, Vignanamaya kosam was 
affected in (8) 20% of cases, Aanandhamaya kosam was affected in (40) 100% of cases. 
 
Observation with reference to ezhu udal thathukkal :  
     In ezhu udal thathukkal Saaram (general tiredness, loss of appetite) was 
affected in 26 (65%) cases, Seneer (low hemoglobin level) was affected in 5 (11%) cases, 
Enbu and Moolai was affected in 7 (19%) cases, Suronitham (vaginal discharge) was 
affected in all cases. 
 
Observation with reference to vatham :  
Abaanan (vaginal discharge, dysuria, lower abdominal pain) was affected in all 
cases, Viyaanan and Samaanan (pain in the low back and both the knees) was affected in 
23 (59%) cases, Kirukaran (loss of appetite) was affected in 26 (65%) cases, 
Devathaththan (general tiredness ) was affected in 32 (80%) of cases. 
 
Observation with reference to pitham :  
Among 40 patients Anal pitham (loss of appetite) was affected in 26 (65%) cases, 
Ranjaga pitham and Prasagam ( low hemoglobin level, paleness) was affected in 5 (11%) 
cases, Saathagam (low back pain, general tiredness)  was affected in 32 (80%) cases. 
 
Observation with reference to kabam: 
Among 40 patients Kilethagam (loss of appetite) was affected in 26 (65%) cases, 
Santhigam (low back pain, knee joint pain) was affected in 32 (80%) cases. 
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Observation with reference to clinical features: 
Clinical features 
No. of cases Percentage (%) 
Before 
treatment 
After treatment 
(No Response) 
Before 
treatment 
After treatment 
( No Response) 
Profuse, thin, creamy, 
whitish/slightly greenish 
frothy discharge  or curdy 
discharge 
40 6 100% 15% 
Pruritis vulva 32 8 80% 20% 
Inflammation of the 
Vulva 
6 0 15% 0% 
Dysuria 18 0 45% 0% 
Lower Abdominal pain 27 3 68% 8% 
Low backache 30 14 75% 35% 
Dyspareunia 13 4 32% 10% 
 
Observation with reference to chronicity of illness: 
                 Among 40 patients 13(33%) cases suffered from  this disease up to 6 months, 
17 cases (42%) suffered upto 1 year, 6 (15%) cases suffered up to 3 years, 4 (10%) cases 
suffered up to 5 years. 
 
Observation with reference to chronicity of illness: 
   Among 40 patients ,13 (31%) cases showed positive to wet test in before 
treatment and 8 (20%)cases showed negative to wet test in after treatment, 27 (69%) 
cases showed positive to KOH for fungus in before treatment and 18 (45%) cases showed 
negative to KOH for fungus in after treatment. 
 
Results: 
   Among 40 patients ,13 (31%) cases showed positive to wet test in before 
treatment and 8 (20%)cases showed negative to wet test in after treatment, 27 (69%) 
cases showed positive to KOH for fungus in before treatment and 18 (45%) cases showed 
negative to KOH for fungus in after treatment. 
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SUMMARY 
  
 This study has been approved by  IEC of NIS [IEC Approval no: NIS/IEC/8-14/2-
26-08-2014] 
 Getting authentication for mineral ingredient of Padigaram in Padigara parpam 
was done from Siddha Central Research Institute, Arumbakkam, Chennai  106.  
 Purification of raw drugs and preparation of trial drug were done in  NIS  
Gunapadam Laboratory, Department of Gunapadam.   
 The Qualitative analysis of the PADIGARA PARPAM was done in Biochemistry 
laboratory, National Institute of Siddha.   
o Silicate ,Chloride and Calcium  are present in Padigara parpam. 
 The physico chemical analysis of Padigara parpam shows, 
 
o Loss on drying at 105°C           =  4.39% 
o Total ash       =  77.597% 
o Water soluble ash      =  12.105% 
o Acid insoluble ash      =  36.993% 
o pH        =  3.80 
 
 The drug was subjected to quantitative  analysis and morphological study ( ICP-
OES and SEM) in IIT, Chennai. Padigara parpam shows the quantitative 
measurement of the following minerals ,  
 
 Al 396.152         4.025 mg/L 
 Ca 315.807 02.360 mg/L 
 K 766.491 123.821 mg/L 
 Mg 285.213 01.304 mg/L 
 Na 589.592 04.310 mg/L 
 P 213.617 16.341 mg/L 
 S 180.731 21.324 mg/L 
 
 The morphology of the Padigara parapam drug can be determined by SEM (FEI 
Quanta). A representative portion of each sample must be sprinkled onto a double 
 127 
 
side carbon tape and mounted on aluminium stubs, in order to get a higher quality 
secondary electron image for SEM examination. We have observed from SEM 
photographs that particles are spherical in shapes and sizes are in the range from 
0.5 micron  to 4 microns. Although the particle sizes of different batches showed 
similarity, it seems that these particles are aggregates of much smaller particles. 
When dispersed in an aqueous medium, these preparations form a negatively 
charged hydrophobic particle suspension. This hydrophobicity gives these 
particles a tendency to aggregate together to form larger particles. This parpam 
exhibited larger sizes and agglomeration of the particles. Therefore, the 
comparatively larger size may be due to the agglomeration of the particles by 
repeated cycles of calcinations involved in preparation. 
 
 The toxicological studies of Padigara parpam was done in K.K college of 
pharmacy, Gerukambakkam. 
 
 Acute toxicity: 
o In the acute toxicity study, the rats were treated with different 
concentration of P. Parpam from the range of 5mg/kg to 2000mg/kg which 
did not produce signs of toxicity, behavioral changes, and mortality in the 
test groups as compared to the controls when observed during 14 days of 
the acute toxicity experimental period. These results showed that a single 
oral dose of the extract showed no mortality of these rats even under 
higher dosage levels indicating the high margin of safety of this extract. In 
acute toxicity test compound P.Parpam was found to be non toxic at the 
dose level of 2000mg/ kg body weight.  
 
Sub acute toxicity 
o The dose selected for the sub acute toxicity study was 200mg, 400mg/kg. 
All the animals were free of intoxicating signs throughout the dosing 
period of 28 days. No physical changes were observed throughout the 
dosing period. No mortality was observed during the whole experiment. 
No significant changes were observed in the values of different parameters 
studied when compared with controls and values obtained were within 
normal biological and laboratory limits. The weights of organs recorded 
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did not show any significant differences in the treatment and the control 
group indicating that P. Parpam was not toxic to kidney, liver, spleen, 
brain There was no significant changes were observed in hemoglobin 
(Hb), red blood cell (RBC), white blood cell (WBC), packed cell volume 
(PCV), Erythrocyte sedimentation rate (ESR) in all the treated groups as 
compared to respective control groups. 
The histopathologial reports shows the following features, 
o Normal liver cells with hepatocyte , central vein and portal triad . 
o Kidneys cells showed less number of degenerated cells.  
o Spleen cells showing normal histology white pulp, red pulp and central 
arteriole. 
o Brain cells with mild degeneration in the cortex. 
 80 cases were screened by using screening form.  
 40 cases of Kirumi yoni rogam were diagnosed clinically and  treated in the  
 OPD of dept. of Maruthuvam, Ayothidoss pandithar hospital, National Institute of 
Siddha.  
 All the patients were treated with PADIGARA PARPAM (Internal  medicine) 
after food twice a day with ghee for  24 days.                
 Among 40 patients 51% of cases (21) were under poor socio-economic status, 
29% of cases (11) were from middle class family and 20% of cases (8) were from 
rich. 
 This study showed  that among 40 patients ,13 cases(31%)  showed positive to 
wet test Trichomonas vaginalis)  in before treatment and 8 cases(20%) showed 
negative to wet test in after treatment, 27 cases(69%)  showed positive to KOH for 
fungus(Candida albicans) in before treatment and 18 cases(45%)  showed negative 
to KOH for fungus in after treatment. 
 Haematological , Urine examination and microbiological studies  were done 
before and after  treatment. 
 The clinical and clinical labarotary Observations  in the Kirumi yoni rogam 
patients treated  with the  trial drug  PADIGARA PARPAM showed reduction in 
the clinical symptoms such as profuse, thin, creamy, whitish/slightly greenish 
frothy discharge  or curdy discharge, pruritis vulva, inflammation of the vulva, 
lower abdominal pain, low back ache, dyspareunia and improvement in their 
general health. The Urine examination showed reduction in pus cells and 
epithelial cells. 
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CONCLUSION 
 
 Siddha way of approach is certainly the best treatment for Kirumi yoni rogam in 
all aspects as the trial drug Padigara parpam  shows marked reduction in the 
clinical symptoms, pus cells and prevents the infection. 
 With the evidence of statistical report, it showed the clinical symptoms before 
treatment and after treatment were 3.225 and 1.025 respectively and the reduction 
of clinical symptoms was highly significant. The percentage of reduction of 
clinical symptoms is 68.22%(1.025÷3.225×100=31.78,100-31.78=68.22%). 
 The Total cell count  before treatment and after treatment were 7564.75 and 7830 
respectively and it was not  highly significant.  
 The Pus cells before treatment and after treatment were 5.15 and 3.75 respectively 
and the reduction of pus cells  was moderately significant. 
 The epithelial cells before treatment and after treatment were 5.2 and 3.95 
respectively and it was not significant. 
 Clinical study revealed that the trial drug possesed good clinical improvement in 
68.22%. 
 Among 40 patients ,13 cases (31%) showed positive to wet test in before 
treatment and 8 cases(20%) showed negative to wet test in after treatment, 27 
cases (69%) showed positive to KOH for fungus in before treatment and 18 cases 
(45%) showed negative to KOH for fungus in after treatment 
 Because of the hopeful results clinically , the study may be undertaken with the 
same drug for a prolonged period  in more number of cases and it may throw new 
lights in the managemet  of  Kirumi yoni rogam.  
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI  47 
 AYOTHIDOSS PANDITHAR HOSPITAL  
DEPARTMENT OF   MARUTHUVAM 
                       Safety and Clinical evaluation of siddha drug   
(Internal)  in   
                             FORM l - SCREENING AND SELECTION PROFORMA 
 
  
 ADDRESS: 
CONTACT NO:              
INCLUSION CRITERIA  
 Age:21-45 yrs, married female                                                                                Yes / No 
 Patient having the symptoms of profuse,thin,frothy whitish/Slightly greenish  
Discharge  or curdy discharge per vagina                                                                Yes / No                                
 Pruritis vulva, inflammation of the vulva, dysuria, lower abdominal pain,  
 low backache, dyspaerunia                                                                                      Yes / No 
 Patient willing to cooperate for vaginal swab examination                               Yes / No            
 Patient willing to undergo routine blood investigation                  Yes / No 
 Positive -Wet test for Trichomonas vaginalis/KOH for fungus                               Yes / No 
 Patient  willing to participate in trial and signing in consent form                Yes /No 
EXCLUSION CRITERIA:  
 History of Diabetes mellitus                  Yes / No 
 History of Bacterial vaginosis                                                                                  Yes / No 
 History of STD (Syphilis,HIV,gonorrhoea)                                        Yes / No 
 History of non specific leucorrhea                                                                 Yes / No                                                                                
 Pregnancy and lactation                               Yes / No                                                   
 History of Malignancy                                                                                            Yes / No 
 
 ADMITTED TO TRIAL  
              YES           NO  
   
                         If Yes Serial NO: 
Date:             Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                           Signature of the HOD:  
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                                  NATIONAL INSTITUTE OF SIDDHA, CHENNAI  47 
                                                AYOTHIDOSS PANDITHAR HOSPITAL  
                                                   DEPARTMENT OF MARUTHUVAM 
              Safety and Clinical evaluation of siddha drug   (Internal) 
                                                         in  
FORM II- CASE RECORD FORM 
1. STUDY NO -----------                              2. OP/IP NO ------------------           REG NO:  
3.  NAME ---------------------------                4. . Age (years): ________    Height: ____ m  Weight: 
______ Kg                               
5. Educational Status: 
1) Literate        2) Illiterate                                  
6. Occupation:                                            
7. Marital Status:   1.Married             2 .Unmarried 
If married;     Gravidity                            Parity 
Dyspareunia -    Present                          Absent 
8. Complaints and Duration:   
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
 
MENSTRUAL HISTORY 
       1. Age at menarche _______ year 
 
      2. Regularly of cycle     Regular                              Irregular  
      3. Length of cycle [Days] 
      4. Duration of flow [Days]           
      5. Dysmenorrhoea started at age _______ years 
     6. Presence of abdominal pain other than around the time of menstruation 
        1. Yes                     2.No 
 VAGINAL DISCHARGE 
1. Colour-       a.Yellow              b.Green           c.White              d.Blood stained 
 
2. Consistency-     a.Thin                    b.Thick                   c.Creamy 
 
3. Amount-       a.Mild                  b.Moderate              c.Profuse 
 
4. Odour:                         1.Yes                              2.No 
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VAGINAL EXAMINATION: 
                   Inflammation of the vulva                                Yes/No 
                   Inflammation of the labia                                  Yes/No 
                   Inflammation of the clitoris                               Yes/No 
                   Inflammation of the urethral meatus                 Yes/No 
                   Inflammation of the vaginal orifice                   Yes/No 
                   Inflammation of the bartholin gland                 Yes/No 
P.V Examination: 
Internal genitalia: 
                  Tenderness of the vulva                                    Yes/No 
                  Scars/Laceration of vagina                                Yes/No 
                  Bleeding from the cervix                                   Yes/No 
 
MEDICAL/SURGICAL HISTORY 
            Diabetes mellitus                                              1.Yes                              2.No 
            Bacterial vaginosis                                            1.Yes                            2.No 
            STD (syphilis, HIV, gonorrhoea)                     1.Yes                            2.No 
            Malignancy                                                       1. Yes                            2.No 
 FAMILY HISTORY 
              Whether this problem runs in family?     1. Yes                2.No            
              
 If yes, mention the relationship of affected person(s) 
                                               1._________________ 
                                               2._________________ 
                                               3._________________ 
 
DIETARY STYLE     
  1.Pure vegetarian                                 2.Non-vegetarian               
 
BOWEL HABITS & MICTURITION: 
             History of habitual constipation              1.Yes               2.No                                                       
             History of frequent diarrhoea                  1.Yes              2.No                                                         
             History of frequent dysuria                      1.Yes              2.No                        
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7. THEGI: [TYPE OF BODY CONSTITUTION]    
Vatham predominant  Kabam predominant  
Pitham predominant  Thondha udal  
 
8. NILAM: [LAND WHERE PATIENT LIVED MOST]               
Kurinji               Mullai                 Marutham             Neithal              Palai   
(Hilly terrain)      (Plains)                (Coastal belt)        (Aridregions)    (Forest range) 
9. KAALAM:[SEASON] 
Kaarkalam            Pinpanikalam      
Koothirkalam   Ilavenil  
Munpanikalam   Muthuvenil 
10. GUNAM:[CHARACTER] 
Sathuvam                        Rasatham                       Thamasam                                   
 
 DAY OF ASSESSMENT   :    
                       0th day                   6h day                12th day                   18th day         
                       24th day                
SIDDHA SYSTEM OF EXAMINATION: 
1. ENVAGAI THERVU: [EIGHT-FOLD EXAMINATION] 
 I.NAADI: [PULSE PERCEPTION] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0th day 6th day 12th day 18th day     24th day      
Date                       
Vali      
Azhal      
Iyyam      
Vali Azhal      
Azhal vali      
Iyya vali      
Vali Iyyam      
Azhal 
Iyyam 
     
Iyya Azhal      
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II.NAA:[TONGUE] 
 0th day 6th day 12th day 18th day 24th day 
Date      
Colour normal/ Red 
pale/yellow 
normal/ 
Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
Taste Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour
/ Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Coating Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Fissure Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Saliva Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Dryness Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Glossiti
s 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Baldnes
s 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 
 
III.NIRAM: [COMPLEXION]    
0th day 6th day 12th day 18th day 24th day 
Date     
Dark/pale/ 
Yellow 
tinted/ 
wheatish 
brown 
Dark/pale/ 
Yellow tinted/ 
wheatish brown 
Dark/pale/ 
Yellow tinted/ 
wheatish 
brown 
Dark/pale/ 
Yellow tinted/ 
wheatish brown 
Dark/pale/ 
Yellow tinted/ 
wheatish brown 
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IV.MOZHI: [VOICE] 
 
0th day 6th day 12th day 18th day 24th day 
Date     
Medium/ 
High/ 
Low 
pitched 
Medium/ 
High/ 
Low 
pitched 
Medium/ 
High/ 
Low 
pitched 
Medium/ 
High/ 
Low 
pitched 
Medium/ 
High/ 
Low 
pitched 
 
V.VIZHI: [EYES] (Lower palpebral conjunctiva)     
0th day 6th day 12th day 18th day 24th day 
Date     
normal/ 
Red 
pale/yellow 
Normal/Red 
pale/yellow 
normal/Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
                                                  
 VI. MALAM:[BOWEL HABITS / STOOLS] 
 0th day 6th day 12th day 18th day 24th day 
Date      
Colour Dark/pale
/ 
yellow/ 
Red 
Dark/pale
/ 
yellow/ 
Red 
Dark/pale/ 
Yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Dark/pal
e/ 
yellow/ 
Red 
Consistency Solid/ 
Semisoli
d/Watery 
Solid/ 
Semisoli
d/Watery 
Solid/ 
Semisolid/
Watery 
Solid/ 
Semisolid/W
atery 
Solid/ 
Semisoli
d/Watery 
stool  bulk                         Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Constipation   Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Diaarhoea Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
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VII.MOOTHIRAM: [URINE EXAMINATION]  
 
Neerkkuri 0th day 6th day 12th day 18th day 24th day 
Date      
Niram[Colour] 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal 
clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal 
clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal 
clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal clear 
Manam[Odour
] 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ Absent 
Nurai[Froth] 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Edai[Sp.gravit
] 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased
/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Enjal[Deposits
] 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ Absent 
Volume 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased
/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
                                      
Neikkuri 0th day 6th day 12th day 18th day 24th day 
Date      
Serpentine fashion at___mints at___ mints at___ mints at___ mints at___ mints 
Annular/Ringed 
fashion 
at___mints at___ mints at___ mints at___ mints at___ mints 
Pearl beaded 
fashion 
at___mints at___ mints at___ mints at___ mints at___ mints 
Mixed fashion at___mints at___ mints at___ mints at___ mints at___ mints 
Other fashion at___mints at___ mints at___ mints at___ mints at___ mints 
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VIII. SPARISAM: [PALPATORY PERCEPTION] 
 
0th day 6th day 12th day 18th day 24th day 
Date     
Warmth/Hot/ 
cold/ Sweat 
Warmth/Hot
/cold/ Sweat 
Warmth/Hot 
/cold/ Sweat 
Warmth/Hot/ 
cold/ Sweat 
Warmth/Hot/ 
cold/ Sweat 
 
 
2. IYMPORIGAL:[SENSORY ORGANS] 
 0th day 6th day 12th day 18th day 24th day 
Date      
 
Normal/ 
Affected 
Normal
/ 
Affecte
d 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Mei [Skin]      
Vaai[Bucc
al cavity] 
     
Kan [Eyes]      
Mooku[No
se] 
     
Sevi [ear]      
 
 
3. IYMPULANGAL: [MOTOR ORGANS] 
 
0th 
day 
6th day 12th day 18th day 24th day 
Date      
 
Norm
al/ 
Affect
ed 
Normal
/ 
Affecte
d 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Kai 
[upperlimb] 
     
Kal      
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[lowerlimb]  
Vai[Buccal 
cavity] 
     
Eruvai 
[excretory 
organ] 
     
Karuvai[ 
Reporduc-tive 
organ] 
     
 
4. KOSAM: [SHEATHS] 
  
 
0th day 6th day 12th day 18th day 24th day 
Date      
 Normal
/  
Affecte
d       
Normal
/  
Affecte
d       
Normal/  
Affected      
Normal/  
Affected      
Normal/  
Affected      
Annamaya 
kosam 
 
     
PranamayaKos
am 
     
Manonmayako
sam 
 
     
Vingyanamaya 
kosam 
     
Anandhamaya 
kosam 
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5. MUKKUTRAM: [AFFECTION OF THREE HUMORS 
A) VATHAM:                                                                          
 0th day 6th day 12th day 18th day 24th day 
Date      
 Normal
/  
Affecte
d       
Normal
/  
Affecte
d       
Normal/  
Affected      
Normal/  
Affected      
Normal/  
Affected      
Praanan      
Abaanan       
Samaanan      
Udhaanan      
Viyaanan      
Naahan      
Koorman      
Kirukaran      
Devathathan      
Dhananjeyan .....  ......   ......    -----   ------- 
 
 
B) PITHAM:               
 0th day 6th day 12th day 18th day 24th day 
Date      
Analapitham Normal
/  
Normal
/  
Normal/  Normal/  Normal/  
 Prasakam Affecte
d       
Affecte
d       
Affected      Affected      Affected      
Ranjakam      
Aalosakam      
Saathakam      
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C) KABAM:                        
 0th day 6th day 12th day 18th day 24th day 
Date      
 Normal/  
Affected      
Normal
/  
Affecte
d       
Normal/  
Affected      
Normal/  
Affected      
Normal/  
Affected      
Avalambaga
m 
     
Kilethagam      
Pothagam      
Tharpagam       
Santhigam      
                
 
6. SEVEN DHATHUS: [SEVEN SOMATIC COMPONENTS]                                         
 0th day 6th day 12th day 18th day 24th day 
Date      
 Normal/  
Affected      
Normal
/  
Affecte
d       
Normal
/  
Affecte
d       
Normal/  
Affected      
Normal/  
Affected      
Saaram[chyme]      
Senneer[Blood]       
Oon[Muscle]      
Kozhuppu[Fat]      
Enbu[Bones]      
Moolai[Bonemarr
ow] 
     
Sukkilam/Suronit
ham  
[Genital 
discharges] 
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7.SYSTEMIC EXAMINATION: 
 0th day 6th day 12th day 18th day 24th day 
Date      
CardioVascular 
System           
     
Respiratory  
System       
     
Gastrointestinal 
System     
     
 
8.GENERAL EXAMINATION: 
 0th day 6th day 12th day 18th day 24th day 
Date      
Height (cms)  NA NA NA NA 
Weight (kg)      
Temperature(°F)  NA NA NA NA 
Pulse rate (per min)      
 
Heart rate (per 
min) 
     
Respiratoryrate(per 
min) 
     
Blood 
pressure(mm/Hg) 
     
Pallor      
Jaundice      
Cyanosis      
Lymphadenopathy      
Pedal edema      
Clubbing      
Jugular vein 
pulsation 
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1. CLINICAL SYMPTOMS: 
 
0th 
day 
6th day 12th day 18th day 
24th 
day 
Date      
Profuse, thin, creamy, 
whitish/slightly greenish 
frothy discharge  or 
curdy discharge 
     
Pruritis vulva      
Inflammation of the 
Vulva 
     
Dysuria      
Lower Abdominal pain      
Low backache      
Dyspareunia      
 
 
 
 
Date: 
Station: 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                               Signature of the HOD: 
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                                      NATIONAL INSTITUTE OF SIDDHA, CHENNAI  47,  
AYOTHIDOSS PANDITHAR HOSPITAL 
                                                 DEPARTMENT OF   MARUTHUVAM 
            Safety and Clinical evaluation of siddha drug   (Internal) in  
                                           
                                                   FORM IV -DRUG COMPLIANCE FORM 
S. NO: ---------   OPD/IPD NO: ---------------     NAME: -----------------------            REG NO:  
Name Of The Drug: Padigara parpam-130 mg bid after food 
 
DAY DATE MORNING 
EVENING 
 
DAY1    
DAY2    
DAY3    
DAY4    
DAY5    
DAY6    
DAY7    
DAY8    
DAY9    
DAY10    
DAY11    
DAY12    
DAY13    
DAY14    
DAY15    
DAY16    
DAY17    
DAY18    
DAY19    
DAY20    
DAY21    
DAY22    
DAY23    
DAY24    
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI  47 
AYOTHIDOSS PANDITHAR HOSPITAL 
DEPARTMENT OF MARUTHUVAM 
 
Safety and Clinical evaluation of siddha drug   (Internal)  
in  
FORM III   LABORATORY INVESTIGATION FORM 
1. OP/IP No: ________                          2 .S. No:                                  3.Reg no:   
       
BLOOD INVESTIGATION 
Before 
treatment 
Date: 
After 
treatment 
Date: 
NORMAL 
VALUES 
HB (gms %)              11-15 
T.RBC(milli/cu.mm)              3.5-5.5 
ESR (mm) 
½ hr.    
1 hr.              0-20 
T.WBC (cu.mm) 
                       
       4000-11,000 
 
 
DIFFERENTIAL 
COUNT (%) 
Polymorphs   40-75 
Lymphocytes   20-35 
Monocytes   2-10 
Eosinophils   1-6 
Basophils   0-1 
Blood glucose (mg/dl) 
Fasting   80-120 
PP   <130 
Random   <140 
Lipid profile (mg/dl) 
Serum cholesterol           150-250 
HDL             30-60 
LDL          Upto 130 
VLDL               40 
TGL         Upto 160 
RFT (mg/dl) 
Blood urea                     16-50 
Serum creatinine                     0.6-1.2 
Serum Uric acid                  2.5-7.5 
LFT (mg/dl) 
Total bilirubin            0.2-1.2 
Direct bilirubin             0.1-1.2 
Indirect bilirubin             0.2-0.7 
Serum total 
protein              6-8 
Serum Albumin             3.5-5.5 
Serum globulin             2-3.5 
Serum fibrinogen    
Serum calcium             9-11 
Serum 
phosphorous             2-5 
SGOT   IU/L             0-40 
SGPT  IU/L              0-35 
Alkaline 
phosphatase  
IU/L 
            80-290 
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  URINE INVESTIGATION 
Urine investigation Before TMT(with Date) After TMT (With Date) 
Albumin   
Fasting sugar   
PP sugar   
Random Sugar   
Deposits   
Bile salts   
Bile pigments   
Urobilinogen   
 
MICROBIOLOGY 
         SEROLOGY 
          
Before treatment   
Date: 
After treatment 
 Date: 
 
    
 VDRL 
 
 
 
 
SPECIAL INVESTIGATION 
VAGINAL SMEAR 
Before treatment 
Date: 
After treatment 
Date: 
WET TEST FOR 
TRICHOMONAS VAGINALIS 
 
 
 
KOH  FOR FUNGUS   
 
 
Date: 
Station: 
 
 
Signature of the Investigator: 
Signature of the Lecturer:                                                                             Signature of the HOD: 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI  47 
AYOTHIDASS PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
Safety and Clinical evaluation of siddha drug   (Internal) 
in KIRUMI YONI  ROGAM   
FORM V- PATIENT INFORMATION SHEET 
Name of the Principal Investigator: Dr.N.Elavarasi (PG Student)                                                 
Name of the Institution                   :  National Institute of Siddha 
                                                              TambaramSanatorium 
                                                              Chennai-47. 
 
               I Dr.N.Elavarasi studying M.D (Siddha) in National Institute of Siddha, Chennai. I am 
doing a clinical trial on the study of Kirumi yoni rogam. It is the specific vaginal infection like 
Trichomoniasis, Moniliasis etc. Trichomoniasis is the most common easily curable Sexually 
transmitted disease. The factors like increasing age,illiteracy,low socioeconomic status, high 
parity, induced abortion & place of delivery are all contributing factors for occurrence of vaginal 
discharge. It includes symptoms of Profuse, thin, creamy whitish/yellowish discharge ,Vulval 
irritation, Pruritis vulva, Dysuria, Abdominal pain, Low backache, Dyspareunia. Moniliasis is 
caused by candida albicans, a gram positive yeast like fungus. The patient complains of curdy 
white vaginal discharge with intense vulvovaginal pruritis. The predisposing factors are diabetes, 
pregnancy, use of broad spectrum antibiotics, combined oral contraceptive pills, steroids, 
immunosuppression-HIV, thyroid and parathyroid disease. This condition is being treated in NIS 
with many siddha formulations.  
              As a part of M.D(S) research programme and developing new efficacious medicine, I 
have proposed to study the drug Padigara parpam for treating this condition. This formulation 
has been mentioned in siddha literature and empirical evidence with contemporary tools is 
required for documentation. You can receive medicines free of cost. The duration of treatment 
period is 24 days. You have to visit NIS 6 days once and collect drugs for 6days. The diagnosis 
tests will be carried out free of cost.We will assess the effect of treatment after completion of 
24days of treatment using clinical and lab parameters. 
              In this regard, I need to ask you few questions. I will maintain confidentiality of your 
comments and data obtained from you. There will be no risk of disclosing your identity and no 
physical, psychological or professional risk is involved by taking part in this study. 
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               Taking part in this study is voluntary. No compensation will be paid to you for taking 
part in this study. You can choose not to answer any specific question. There is no specific benefit 
for you if you take part in the study, but you will be under our clinical monitoring and specific 
attention will be given for your health. Taking part in the study may be of benefit to the 
community, as it may help us to develop medicine for Kirumi yoni rogam. In case of any adverse 
symptoms like severe low back pain, increased profuse white discharge during the treatment shall 
be reported to me and care will be taken in NIS for relief. You can withdraw from the study at the 
midst of treatment period, if you are not interested to continue and you will receive our usual 
treatment without condition. 
                The information collected in this study, will remain between you and me as a principal 
investigator.I will not write your name on different forms which sent to different 
investigating/analysis sections and I will use a code instead given by the principal investigator. 
Only the principal investigator will know the key to this code which will be kept in safe custody. 
If you agree to be a participant in this study, you will be screened as per the study protocol.               
                If you wish to find out more about this study before taking part, you can ask me all the 
questions you want or contact Dr.N.Elavarasi, PG student cum principal investigator of this study, 
attached to the National Institute of Siddha, Chennai (Mobile phone no:9789879343). You can 
also contact the Chairman/Member-secretary of Ethics committee, National Institute of Siddha, 
Chennai  600047, Tel no: 91-44-22411611, for rights and participation in the study. 
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                                          §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ,  
  «§Â¡ò¾¢¾¡º÷ ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
                                                     ¦ºý¨É 47 
¸¢ÕÁ¢§Â¡É¢ §Ã¡¸ §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý (ÀÊ¸¡Ã ÀüÀõ) ÀÃ¢¸Ã¢ôÒò 
¾¢È¨Éì   ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ 
                                          FORM V- ¾¸Åø ÀÊÅõ 
 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡ª÷ ¦ÀÂ÷ :  Dr. ¿¢.­ªÅÃº¢ 
 ¿¢ÚÅÉò¾¢ý ¦ÀÂ÷                  :  §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõs 
                                                  ¾¡õÀÃõ º¡Éð§¼¡Ã¢Âõ 
                                                  ¦ºý¨É 47 
 
              Dr.¿¢.­ªÅÃº¢ ¬¸¢Â ¿¡ý §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø Àð¼ §ÁüÀÊôÒ 
ÀÂ¢ýÚ ÅÕ¸¢§Èý. ¸¢ÕÁ¢§Â¡É¢  §Ã¡¸õ  ±ýÛõ §¿¡Â¡Ìõ ±ª¢¾¢ø Ì½ôÀÎò¾ìÜÊÂ 
´Õ À¡øÅ¢¨É §¿¡Â¡Ìõ. ­ó§¿¡Â¡ÉÐ «¾¢¸ÀÊÂ¡É ¦Åû¨ª ¸º¢×, À¢ÈôÒÚôÀ¢ø 
«Ã¢ôÒ, º¢Ú¿£÷ ±Ã¢îºø, ÓÐÌ ÅÄ¢, Ò½÷îº¢ ÅÄ¢ §À¡ýÈ ÌÈ¢Ì½í¸¨ªò 
§¾¡üÚÅ¢ìÌõ. ­ó§¿¡öìÌ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø ÀÄ º¢ò¾ ÁÕóÐ¸û 
ÀÂýÀÎò¾ôÀðÎ ÅÕ¸¢ýÈÐ. º¢ò¾ ÁÕòÐÅ Àð¼ §ÁüÀÊôÀ¢ø, ¬öÅ¢ý ´Õ ÀÌ¾¢Â¡¸ 
Ò¾¢Â ÁÕóÐ¸¨ª ÀÂýÀÎòÐõ §¿¡ì¸¢ø ÀÊ¸¡Ã ÀüÀõ ±ýÛõ ÁÕó¾¢¨É ­ó§¿¡öìÌ 
ÅÆí¸ ÀÃ¢óÐ¨Ã ¦ºö¸¢§È¡õ. ­ó¾ ÁÕó¾¢ý ¦ºöÓ¨È, «ª×, «ÛÀ¡Éõ ÁüÚõ 
ÁÕòÐÅ ÀÂý¸û «¨ÉòÐõ «í¸£¸Ã¢ì¸ôÀð¼ º¢ò¾ ÁÕòÐÅ áÄ¢ø ÜÈôÀðÎûªÐ. 
±ó¾Å¢¾ ¸ð¼½ÓÁ¢ýÈ¢ ¾¡í¸û ­ó¾ ÁÕó¾¢¨É ¦ÀüÚì¦¸¡ûªÄ¡õ. ­ó¾ ¬öÅ¢ø 
ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äõ 24 ¿¡ð¸û ¬Ìõ. 6 ¿¡û¸ÙìÌ ´ÕÓ¨È §¾º¢Â º¢ò¾ 
ÁÕòÐÅÁ¨ÉìÌ §¿Ã¢ø ÅóÐ ÁÕó¾¢¨É ¦ÀüÚì¦¸¡ûª §ÅñÎõ. ­ó¾ ¬ö× 
ºõÀó¾Á¡É ¬öÅ¸ ÀÃ¢§º¡¾¨É¸û ¸ð¼½Á¢ýÈ¢ ¦ºöÂôÀÎõ. 24 ¿¡ð¸û ÁÕóÐ 
¯ð¦¸¡ûÙõ ¸¡Äõ ÓÊó¾ À¢ÈÌ §¿¡öì¸¡É ÌÈ¢Ì½í¸û ÁüÚõ ¬öÅ¸ 
ÀÃ¢§º¡¾¨É¸û ­ÅüÈ¢ý ÓÊ×¸ª¢ý «ÊôÀ¨¼Â¢ø ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢Èý 
¸ñ¼È¢ÂôÀÎõ.  
        
 ­ó¾ ¬ö× ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨ª ¾í¸ª¢¼õ §¸ð¸ ­Õì¸¢§Èý. 
¾í¸ª¢¼Á¢ÕóÐ ¦ÀÈôÀÎõ ¸ÕòÐì¸û ÁüÚõ ÌÈ¢ôÒ¸û «¨ÉòÐõ ¿õÀ¢ì¨¸Â¡¸ À¾¢× 
¦ºöÂôÀÎõ.­ó¾ ¬öÅ¢ø ¾í¸¨ª ¯ðÀÎò¾¢ì¦¸¡ûÅ¾¢ý ãÄõ ±ó¾ Å¨¸Â¢Öõ 
À¡¾¢ôÒìÌûª¡¸ Á¡ðË÷¸û ±É ¯Ú¾¢ «ª¢ì¸¢§Èý. 
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 ±ó¾Å¢¾ ÅüÒÚò¾ÖÁ¢ýÈ¢, ­ó¾ ¬öÅ¢ø Àí§¸ü¸×õ, ­ó¾ ¬ö× ºõÀó¾Á¡¸ 
§¸ð¸ôÀÎõ §¸ûÅ¢¸ÙìÌ À¾¢ø ÜÈ×õ ¾í¸ÙìÌ ÓØ Í¾ó¾¢Ãõ «ª¢ì¸ôÀÎ¸¢ÈÐ. 
­ó¾ ¬öÅ¢ø Àí§¸üÀ¾üÌ ±ó¾ ºýÁ¡ÉÓõ ÅÆí¸ôÀ¼Á¡ð¼¡Ð.  ¬É¡ø, ¬ö× 
ÓØÅÐõ ±ÉÐ §ÁüÀ¡÷¨ÅÂ¢Öõ, ¾í¸û ¯¼ø¿Äý ÌÈ¢ò¾ ¾É¢ ¸ÅÉò¾¢Öõ ¬ö× 
§Áü¦¸¡ûªôÀÎõ. ¸¢ÕÁ¢§Â¡É §Ã¡¸õ §¿¡öì¸¡É Ò¾¢Â ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢È¨É 
ºã¸ò¾¢üÌ ¯½÷òÐõ Å¨¸Â¢ø ­ó¾ ¬ö× §Áü¦¸¡ûªôÀÎ¸¢ÈÐ. ­ó¾ ¬öÅ¢ø, 
ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äò¾¢ø º¢ÄÕìÌ Á¢¸ «¾¢¸ÀÊÂ¡É ¦Åû¨ª ¸º¢× , 
¾¡í¸ÓÊÂ¡¾  ÓÐÌÅÄ¢ §À¡ýÈ Á¡ÚÀð¼ ÌÈ¢Ì½í¸û ¦¾¡¼÷óÐ ­ÕìÌõ 
Àðºò¾¢ø, Ó¾ý¨Á ¬Ã¡öîº¢Â¡ªÃ¡É ±ýÉ¢¼õ ¦¾Ã¢Å¢ì¸ôÀðÎ, §¾º¢Â º¢ò¾ 
ÁÕòÐÅÁ¨ÉÂ¢ø «¾üì¸¡É ¾£÷× ÅÆí¸ôÀÎõ. ­ó¾ ¬öÅ¢¨Éò ¦¾¡¼Ã ¾í¸ÙìÌ 
Å¢ÕôÀõ ­ø¨Ä¦ÂÉ¢ø, ±ô¦À¡ØÐ §ÅñÎÁ¡ÉÖõ ¬öÅ¢ý ­¨¼Â¢ø 
Å¢Ä¸¢ì¦¸¡ûª×õ, ­õÁÕòÐÅÁ¨ÉÂ¢ø ÅÆí¸ôÀÎõ ­ó§¿¡öì¸¡É ÅÆì¸Á¡É 
ÁÕóÐ¸¨ª ¦ÀüÚì¦¸¡ûª×õ «È¢×Úò¾ôÀÎ¸¢È£÷¸û. 
        
 ­ó¾ ¬öÅ¢ø §º¸Ã¢ì¸ôÀÎõ Å¢ÀÃí¸û «¨ÉòÐõ ¾í¸ÙìÌõ Ó¾ý¨Á 
¬Ã¡öîº¢Â¡ªÃ¡É ±ÉìÌõ ­¨¼Â¢ø Ã¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ. §¸ûÅ¢ À¾¢ø ÅÊÅò¾¢ø 
¾í¸ª¢¼õ §¸ûÅ¢¸û §¸ð¸ôÀÎõ. «¨ÉòÐô ÀÊÅí¸ª¢Öõ ¾í¸ª¢ý ¦ÀÂ÷ 
¾Å¢÷ì¸ôÀðÎ ¬öÅ¡ªÃ¡ø ¾í¸Ùì¦¸É ¾É¢ì ÌÈ¢Â£Î ÅÆí¸ôÀÎõ. «ó¾ì ÌÈ¢Â£Î 
¬öÅ¡ªÕìÌ ÁðÎ§Á ¦¾Ã¢ó¾¾¡¸ ­ÕìÌõ. ¿£í¸û ­ó¾ ¬öÅ¢ø Àí§¸ü¸ 
Å¢ÕôÀôÀð¼¡ø, ¾¢ð¼ Å¨Ã× ÀÊ §¾÷× ¦ºöÂôÀÎÅ£÷¸û. 
         
 ¿£í¸û ­ó¾ ¬öÅ¢ø Àí§¸üÌõ Óý, ­ó¾ ¬öÅ¢¨Éô ÀüÈ¢Â §ÁÖõ Å¢ÀÃí¸û 
¦ÀÈ §ÅñÎ¦ÁÉ Å¢ÕôÀôÀð¼¡ø, ­ó¾ ¬öÅ¢ý Ó¾ý¨Á ¬Ã¡öîº¢Â¡ª÷ ÁüÚõ 
§¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É,Àð¼ §ÁüÀÊôÒòÐ¨È Á¡½Å¢  Dr.¿¢.­ªÅÃº¢ ¬¸¢Â ±ý¨É 
9789879343 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò ¦¸¡ûªÄ¡õ. §ÁÖõ, ¿£í¸û ­ó¾ ¬öÅ¢ø, 
¯í¸ªÐ Àí§¸üÒ ÁüÚõ ¯Ã¢¨Á ÀüÈ¢ ¦¾Ã¢óÐ ¦¸¡ûª §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É, 
¾¨ÄÅ÷/¦ºÂüìÌØ ¯ÚôÀ¢É÷ «Å÷¸¨ªÔõ 91-44-22411611 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò 
¦¸¡ûªÄ¡õ.   
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI  47 
AYOTHIDOSS PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
 
Safety and Clinical evaluation of siddha drug   (Internal) 
in  
FORM VI INFORMED CONSENT FORM 
 I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask questions about it and any questions I have asked have been answered to my 
satisfaction.  
            I   consent voluntarily to participate in this study and understand that I have the right to 
withdraw from the study at any time without in any way it affecting my further medical care . 
           "I have received a copy of the information sheet/consent form". 
Date: 
Signature of the participant: 
In case of illiterate participant 
  I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm that the 
individual has given consent freely  
 
 
Date: 
 
 Signature of a witness                                            Left thumb Impression of the Participant     
(Selected by the participant bearing no connection with the survey team)      
 
 Date:    
Station: 
                                                                                  
Signature of participant:                                                 
Signature of the Investigator: 
Signature of the Lecturer:                                                          Signature of the HOD       
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                       §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
«§Â¡ò¾¢¾¡º ÀñÊ¾÷ ÁÕòÐÅÁ¨É, ¦ºý¨É - 47. 
Àð¼ §ÁüÀÊôÒ ÁÕòÐÅòÐ¨È 
   
¸¢ÕÁ¢§Â¡É¢ §Ã¡¸ §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý (ÀÊ¸¡Ã ÀüÀõ) ÀÃ¢¸Ã¢ôÒò 
¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ  
                      
                        FORM  VI-  ´ôÒ¾ø ÀÊÅõ 
 
                ¿¡ý §ÁüÜÈ¢Â  ¾¸Åø  ÀÊÅò¨¾ ÀÊòÐ «øÄÐ ÀÊì¸ §¸ðÎ 
¦¸¡ñ§¼ý. Ð ¦¾¡¼÷À¡É Å¢ªì¸í¸¨ªÔõ §¸ðÎ ¦¾Ã¢óÐ ¦¸¡ñ§¼ý. ±ó¾ 
Å¢¾ ÅüÒÚò¾Ä¢ýÈ¢, ±ý ¦º¡ó¾ Å¢ÕôÀò¾¢ý §ÀÃ¢ø ±ý¨É ó¾ ¬Ã¡öîº¢ìÌ 
¯ðÀÎò¾ ±ý ÓØÁÉ§¾¡Îõ ÍÂ¿¢¨É§Å¡Îõ ºõÁ¾õ ¦¾Ã¢Å¢ì¸¢ý§Èý. ±ÉìÌ 
Å¢ÕôÀÁ¢øÄ¡¾ Àðºò¾¢ø ­ó¾ ¬Ã¡öîº¢Â¢ø ­ÕóÐ ±ý¨É ±ô§À¡Ð 
§ÅñÎÁ¡É¡Öõ Å¢ÎÅ¢òÐ ¦¸¡ûÙõ ¯Ã¢¨Á¨Â ¦ÀüÚû§ªý ±ýÀ¨¾Ôõ 
«È¢§Åý. 
 
 
   
§¾¾¢:                                                                             
­¼õ:                                                                              
                                                                                º¡ðº¢ì¸¡Ã÷ ¨¸¦Â¡ôÀõ: 
                                                                                ¦ÀÂ÷: 
 
¨¸¦Â¡ôÀõ:                                                              ¯È×Ó¨È :                                            
¦ÀÂ÷     : 
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                                NATIONAL INSTITUTE OF SIDDHA, CHENNAI  47 
 AYOTHIDOSS PANDITHAR HOSPITAL  
DEPARTMENT OF   MARUTHUVAM 
 
                  Safety and Clinical evaluation of siddha drug   (Internal) 
                                                             in  
                                                           FORM VII-WITHDRAWAL FORM 
 
2. OP / IP NO: ......................................    
   
 
 
8. REASONS FOR WITHDRAWAL: 
Long absence at reporting:              Yes/ No 
Irregular treatment:                          Yes/ No 
Shift of locality:                                    Yes/No 
Increase in severity of symptoms:    Yes/No 
Development of severe adverse drug reactions:  Yes/No 
 
 
 
Date:          
Station: 
 
Signature of the Investigator: 
Signature of the Lecturer:                                                   Signature of the HOD: 
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NATIONAL PHARMACOVIGILANCE PROGRAMME FOR    
SIDDHA DRUGS 
 
 
 
 
 
Please note:  i.  All consumers / patients and reporters information will remain confidential. 
         ii. It is requested to report all suspected reactions to the concerned, even if  
             it does not have complete data, as soon as possible. 
Peripheral Center code:     State:  
 
1. Patient / consumer identification (please complete or tick boxes below as appropriate) 
 
Name  Father name 
 
Patient / Record No. 
Ethnicity  Occupation 
Address  
Village / Town 
Post / Via 
District / State    
Date of Birth / Age: 
 
Sex:     Male / Female  
Weight : 
Degam: 
 
 
2. Description of the suspected Adverse Reactions (please complete boxes below) 
 
Date and time  of initial 
observation 
 Season: 
Description of reaction   
 
 Geographical area: 
 
 
 
 
 
Reporting Form for Suspected Adverse Reactions to Siddha Drugs 
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3. List of all medicines / Formulations including drugs of other systems used by the patient 
during the reporting period: 
 
Medicine Daily 
dose 
Route of 
administration 
& Vehicle - 
Adjuvant 
Date  Diagnosis for which 
medicine taken  Starting Stopped 
Siddha      
Any other system 
of medicines 
     
 
 
4. Brief details of the Siddha Medicine which seems to be toxic : 
 
Details Drug  1 Drug  2 Drug - 3 
a) Name of the medicine    
b) Manufacturing unit and 
batch No. and date 
   
c) Expiry date    
d) Purchased and obtained from    
e) Composition of the 
formulation / Part of the drug 
used 
   
 
 
a. Dietary Restrictions if any 
b. Whether the drug is consumed under Institutionally qualified medical 
supervision or used as self medication.  
c. Any other relevant information. 
 
 
5. Treatment provided for adverse reaction: 
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6. The result of the adverse reaction / side effect / untoward effects (please complete the 
boxes below) 
 
Recovered: 
Not 
recovered: 
Unknown: Fatal: 
If Fatal 
Date of death: 
Severe:   Yes   /   No. 
Reaction abated after drug stopped or dose reduced: 
 
Reaction reappeared after re introduction: 
 
 
Was the patient admitted to hospital? If yes, 
give name and address of hospital 
 
 
 
7. Any laboratory investigations done to evaluate other possibilities?  If Yes specify:  
 
8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal    Cardiac    Diabetes    Malnutrition    
 
Any Others  
 
9. H/O previous allergies / Drug reactions:  
10. Other illness (please describe) 
11. Identification of the reporter: 
 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / Attendant / 
Manufacturer /                                                                      
                                Distributor / Supplier / Any others (please specify) 
Name: 
 
Address: 
 
Telephone / E  mail if any : 
 
 
 
Signature of the reporter:       Date: 
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Please send the completed form to:  
           The Director 
            National Institute of Siddha, 
                                                                  (Pharmacovigilance Regional Centre For Siddha Medicine), 
                                                                Tambaram Sanatorium, Chennai-600 047. 
                                                                   (O) 044-22381314 Fax : 044  22381314 
        Website : www.nischennai.org  
        Email: nischennaisiddha@yahoo.co.in   
 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ** * * * *  
 
This filled-in ADR report may be sent within one month of observation /occurrence of ADR   
 
Date:                                                                              
Station:  
 
Signature of the Investigator: 
Signature of the Lecturer:                                                             
 
          
 
 
Date:      
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                       Signature of the HOD 
 
 
 
 
 
 
 
 
 
 
 
Who Can Report?     
 Any Health care professionals like Siddha Doctors /  Nurses / Siddha 
Pharmacists / Patients etc.  
What to Report?  
 All reactions,  Drug interactions,  
Confidentiality  
 
fullest extent. 
Name & address of the RRC-
ASU / PPC-ASU 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI  47 
AYOTHIDASS PANDITHAR HOSPITAL 
DEPARTMENT OF MARUTHUVAM 
Safety and Clinical evaluation of siddha drug   (Internal) 
in  
FORM VIII- DIETARY ADVICE FORM 
The following diet to be taken: 
  Drink adequate water 
 Leafy greens & vegetables 
  
 Onion 
 Ginger 
 Steamed vegetables & vegetable salads 
 Riped bananas 
 Lemon or orange juice 
 Apple 
 Black plums 
 Pears 
 Gooseberry 
 Dates 
 Fig fruit 
 Pome granate 
 Grapes 
 Guava 
 Whole wheat 
 Brown rice 
 Milk 
 Butter milk 
 Ghee 
 Fenugreek 
 Coriander seeds 
 Cumin seeds 
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The following food should be avoided: 
 Bitter gourd                                                         
 Chicken  
 Meat     
 Coconut 
 Jack fruit 
 Asafoetida 
 Mango                            
 Brinjal   
 Sesbanian leaves 
 Mustard 
 Sesame                                                                 
 Tamarind 
 Eggs 
 Mushrooms 
 Bread 
 Sweets 
 White sugar 
 Tea 
 Coffee 
 Preserved cool drinks 
 Oily  & fried foods 
 Sour foods 
 
AVOID 
 Tobacco 
 Alcohol  
 Excessive lust                                
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, ¦ºý¨É 47 
«§Â¡ò¾¢¾¡º÷ ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
¸¢ÕÁ¢§Â¡É¢ §Ã¡¸ §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý (ÀÊ¸¡Ã ÀüÀõ) ÀÃ¢¸Ã¢ôÒò 
¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ 
FORM VIII- DIETARY ADVICE FORM 
§º÷ì¸ ÜÊÂ ¯½× Å¨¸¸û: 
 
 ¸£¨Ã¸û, 
 ¦Åñ¨¼ì¸¡ö 
 º¢ýÉ¦Åí¸¡Âõ 
 ­ïº¢ 
 §Å¸¨Åò¾ ¸¡ö¸È¢¸û 
 Å¡¨ÆôÀÆõ 
 ±ÖÁ¢î¨º º¡Ú 
 ¬ôÀ¢û 
 §ÀÃ¢ì¸¡ö 
 ¦¿øÄ¢ì¸É¢ 
 §ÀÃ£îºõÀÆõ 
 «ò¾¢ÀÆõ 
 Á¡Ð¨ª 
 ¾¢Ã¡ð¨º 
 ¦¸¡öÂ¡ 
 §¸¡Ð¨Á 
 ¾£ð¼¡¾ «Ã¢º¢ 
 À¡ø 
 §Á¡÷ 
 ¦¿ö 
 ¦Åó¾Âõ 
 ¾É¢Â¡ 
 º£Ã¸õ                         
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¾Å¢÷ì¸ ÜÊÂ ¯½× Å¨¸¸û 
 À¡¸ø  
 §¸¡Æ¢ì¸È¢  
 ¬ðÎì ¸È¢  
 ¸ò¾Ã¢ 
 «¸ò¾¢ì¸£¨Ã 
 §¾í¸¡ö,Á¡í¸¡ö 
 ±û,¸ÎÌ 
 ÀÄ¡ 
 ¦ÀÕí¸¡Âõ 
 Òª¢  
 Óð¨¼, ¸¡ª¡ý 
 ¦Åû¨ª º÷ì¸¨Ã 
 §¾¿£÷,¸¡À¢ 
 ±ñ¦½ö,  ÅÚò¾ ¯½×¸û,ÐÅ÷ôÒ ¯½×¸û 
 
¾Å¢÷ì¸§ÅñÊÂ¨Å 
 Ò¨¸Â¢¨Ä 
 ¸ûÙ 
 «¾¢¸ÀÊÂ¡É§À¡¸õ. 
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